https://curecurrent.com/trials/a-study-of-mm-121-in-combination-with-chemotherapy-versus-chemotherapy-alone-in-heregulin-positive-nsclc-49001https://curecurrent.com/trials/observation-study-of-patients-with-non-small-cell-lung-cancer-and-esophageal-cancer-treated-with-chemo-radiation-followe-49002https://curecurrent.com/trials/study-of-nivolumab-bms-936558-in-combination-with-gemcitabine-cisplatin-pemetrexed-cisplatin-carboplatin-paclitaxel-beva-49003https://curecurrent.com/trials/feasibility-study-of-enhanced-mri-for-early-stage-non-small-cell-lung-cancer-nsclc-49004https://curecurrent.com/trials/lidocaine-administration-during-flexible-bronchoscopy-and-endobronchial-ultrasound-49005https://curecurrent.com/trials/enoxaparin-versus-placebo-for-venous-thromboembolism-prevention-in-low-risk-cancer-patients-after-surgical-procedures-a-49006https://curecurrent.com/trials/feasibility-study-on-expandion-of-mils-from-nsclc-and-sclc-patients-and-infusion-with-pembrolizumab-49007https://curecurrent.com/trials/effect-of-pulmonary-rehabilitation-on-perioperative-outcomes-in-smoker-patients-with-lung-cancer-49008https://curecurrent.com/trials/the-safety-of-chemotherapy-for-patients-with-gynecological-malignancy-in-high-risk-region-of-covid-19-49009https://curecurrent.com/trials/a-phase-i-trial-of-vandetanib-azd6474-and-selumetinib-azd6244-for-solid-tumours-including-non-small-cell-lung-cancer-van-49010https://curecurrent.com/trials/study-of-two-doses-of-pembrolizumab-mk-3475-versus-docetaxel-in-previously-treated-participants-with-non-small-cell-lung-49011https://curecurrent.com/trials/the-effect-of-the-covid-19-pandemic-on-primary-bladder-cancer-presentations-49012https://curecurrent.com/trials/web-based-intervention-for-lung-cancer-patients-and-their-informal-caregivers-49013https://curecurrent.com/trials/nab-paclitaxel-in-combination-with-carboplatin-as-first-line-therapy-in-patients-with-nsclc-49014https://curecurrent.com/trials/treatment-of-egfr-tki-for-residual-lesions-of-multiple-synchronous-ground-glass-opacities-49015https://curecurrent.com/trials/stereotactic-body-radiotherapy-rt-for-non-small-cell-lung-cancer-49016https://curecurrent.com/trials/impact-of-ehealth-monitoring-on-overall-survival-in-patients-with-metastatic-nsclc-extensive-stage-sclc-advanced-tnbc-un-49017https://curecurrent.com/trials/a-study-of-ds-2248-in-participants-with-advanced-solid-tumors-49018https://curecurrent.com/trials/evaluation-for-benign-and-malignant-pulmonary-ground-glass-nodules-based-on-mri-dynamic-contrast-enhanced-imaging-49019https://curecurrent.com/trials/application-of-ctdna-in-the-evaluation-of-curative-effect-and-prognosis-of-sclc-patients-49020https://curecurrent.com/trials/daily-vs-non-daily-sbrt-for-nsclc-49021https://curecurrent.com/trials/respiratory-endoscopy-diagnostic-yield-technical-factors-and-complications-49022https://curecurrent.com/trials/lung-nodule-prospective-database-49023https://curecurrent.com/trials/eus-b-fna-in-the-diagnosis-of-malignant-parenchymal-lung-lesions-49024https://curecurrent.com/trials/self-management-and-activation-to-reduce-treatment-related-toxicities-smartcare-49025https://curecurrent.com/trials/detection-of-either-the-eml4-alk-gene-rearrangements-or-the-t790m-egfr-mutation-in-the-plasma-of-advanced-nsclc-patients-49026https://curecurrent.com/trials/phase-ii-study-of-abraxane-and-gemicitabine-in-patients-with-advanced-adenocarcinoma-non-small-cell-lung-cancer-progress-49027https://curecurrent.com/trials/intracavitary-cisplatin-fibrin-localized-chemotherapy-after-p-d-or-epp-for-malignant-pleural-mesothelioma-49028https://curecurrent.com/trials/a-study-of-alectinib-in-ret-rearranged-non-small-cell-lung-cancer-or-ret-mutated-thyroid-cancer-49029https://curecurrent.com/trials/envafolimab-as-first-line-treatment-of-aged-patients-in-advanced-nsclc-49030https://curecurrent.com/trials/toripalimab-in-combination-with-platinum-based-chemotherapy-for-mutation-negative-stage-iv-oligometastatic-nsclc-49031https://curecurrent.com/trials/a-national-registry-on-chinese-patients-with-lymphangioleiomyomatosis-49032https://curecurrent.com/trials/efficiency-and-safety-of-microwave-ablation-plus-immune-checkpoint-inhibitor-for-patients-with-multiple-primary-lung-can-49033https://curecurrent.com/trials/a-study-of-atezolizumab-in-combination-with-carboplatin-plus-paclitaxel-with-or-without-bevacizumab-compared-with-carbop-49034https://curecurrent.com/trials/oral-glutamine-and-thoracic-upper-aerodigestive-tumors-radiation-toxicity-49035https://curecurrent.com/trials/prophylactic-cranial-irradiation-in-extensive-stage-small-cell-lung-cancer-49036https://curecurrent.com/trials/pain-after-lung-cancer-surgery-comparing-traditional-versus-prolonged-release-nerve-blockades-49037https://curecurrent.com/trials/a-study-to-evaluate-the-safety-tolerability-and-activity-of-tak-931-in-participants-with-metastatic-pancreatic-cancer-me-49038https://curecurrent.com/trials/a-brief-smart-exercise-instant-messaging-support-intervention-a-pilot-study-49039https://curecurrent.com/trials/pulmonary-function-after-arterial-sleeve-lobectomy-49040https://curecurrent.com/trials/a-multimodality-image-guided-system-for-peripheral-lung-cancer-diagnosis-and-therapy-49041https://curecurrent.com/trials/microdevice-for-evaluating-drug-response-in-site-in-lung-lesions-49042https://curecurrent.com/trials/exploration-of-immunodynamic-monitoring-in-the-population-evaluation-of-neoadjuvant-chemotherapy-immunotherapy-in-patien-49043https://curecurrent.com/trials/radiomics-to-identify-patients-at-risk-for-developing-pneumonitis-differentiate-immune-checkpoint-inhibitor-induced-pneu-49044https://curecurrent.com/trials/tarceva-with-whole-brain-radiation-therapy-brain-mets-from-non-small-cell-lung-cancer-49045https://curecurrent.com/trials/efficacy-and-safety-of-osimertinib-for-hk-chinese-with-metastatic-t790m-mutated-nsclc-real-world-setting-49046https://curecurrent.com/trials/a-comparative-study-of-bat1706-and-eu-avastin-in-patients-with-advanced-non-squamous-non-small-cell-lung-cancer-49047https://curecurrent.com/trials/strategies-to-continue-gynae-oncology-services-in-the-era-of-covid-19-outbreak-concerns-and-challenges-in-a-referral-cen-49048https://curecurrent.com/trials/evaluation-of-the-archimedes-system-for-transparenchymatous-access-to-pulmonary-nodules-49049https://curecurrent.com/trials/treatment-patterns-clinical-outcomes-and-healthcare-resource-utilization-associated-with-chinese-patients-with-advanced-49050https://curecurrent.com/trials/immunogenicity-of-covid-19-vaccination-for-patients-with-hematological-malignancies-49051https://curecurrent.com/trials/safety-efficacy-and-pharmacokinetic-of-bpi-9016m-in-patients-with-c-met-dysregulated-advanced-nsclc-49052https://curecurrent.com/trials/genetically-modified-t-cells-in-treating-patients-with-stage-iii-iv-non-small-cell-lung-cancer-or-mesothelioma-49053https://curecurrent.com/trials/real-world-study-of-mpm-in-china-49054https://curecurrent.com/trials/sln-detection-with-tc-msa-icg-in-lung-cancer-patients-49055https://curecurrent.com/trials/safety-pharmacokinetic-and-preliminary-efficacy-study-of-ac0010-in-patients-with-egfr-t790m-positive-nsclc-49056https://curecurrent.com/trials/camrelizumab-combined-with-local-treatment-in-nsclc-patients-with-bm-49057https://curecurrent.com/trials/chemotherapy-and-radiation-therapy-with-or-without-epoetin-alfa-in-treating-patients-with-stage-iiia-or-stage-iiib-non-s-49058https://curecurrent.com/trials/combination-chemotherapy-plus-thalidomide-in-treating-patients-with-stage-iiib-or-stage-iv-non-small-cell-lung-cancer-49059https://curecurrent.com/trials/a-study-of-galunisertib-ly2157299-in-combination-with-nivolumab-in-advanced-refractory-solid-tumors-and-in-recurrent-or-49060https://curecurrent.com/trials/megestrol-in-treating-patients-who-are-undergoing-radiation-therapy-for-lung-cancer-49061https://curecurrent.com/trials/combination-chemotherapy-in-treating-patients-with-extensive-stage-small-cell-lung-cancer-49062https://curecurrent.com/trials/bepact-lung-impact-of-patient-characteristics-on-pneumo-oncologists-non-small-cell-lung-cancer-nsclc-systemic-treatment-49063https://curecurrent.com/trials/green-tea-combined-with-chemotherapy-in-the-treatment-of-advanced-non-small-cell-lung-cancer-49064https://curecurrent.com/trials/radiomics-based-prediction-model-of-tumor-spread-through-air-space-in-lung-adenocarcinoma-49065https://curecurrent.com/trials/letetresgene-autoleucel-engineered-t-cells-in-ny-eso-1-positive-advanced-non-small-cell-lung-cancer-nsclc-49066https://curecurrent.com/trials/irreversible-electroporation-ire-for-unresectable-hilus-pulmonis-neoplasms-49067https://curecurrent.com/trials/study-of-stereotactic-ablative-radiotherapy-sbrt-followed-by-atezolizumab-tiragolumab-in-treatment-naive-patients-with-m-49068https://curecurrent.com/trials/whether-sputum-can-serve-as-an-alternative-source-for-liquid-biopsy-in-patients-with-lung-cancer-49069https://curecurrent.com/trials/almonertinib-plus-microwave-ablation-in-advanced-non-small-cell-lung-cancer-49070https://curecurrent.com/trials/durvalumab-with-chemotherapy-followed-by-sequential-radiotherapy-for-limited-stage-small-cell-lung-cancer-49071https://curecurrent.com/trials/irreversible-electroporation-ire-for-lung-neoplasms-accompanied-by-respiratory-function-insufficiency-49072https://curecurrent.com/trials/a-study-to-evaluate-the-efficacy-of-osimertinib-with-early-intervention-srs-treatment-compared-to-the-continuation-of-os-49073https://curecurrent.com/trials/neoadjuvant-immunotherapy-and-chemotherapy-followed-by-surgery-in-unresectable-stage-nsclc-49074https://curecurrent.com/trials/dose-painting-radiation-for-la-nsclc-49075https://curecurrent.com/trials/the-efficacy-of-intraoperative-pulmonary-nodules-localization-guided-by-virtual-reality-technology-49076https://curecurrent.com/trials/intracranial-activity-of-azd9291-tagrisso-in-advanced-egfrm-nsclc-patients-with-asymptomatic-brain-metastases-49077https://curecurrent.com/trials/self-breathe-for-chronic-breathlessness-49078https://curecurrent.com/trials/patients-preferences-about-rescheduling-colonoscopies-delayed-due-to-covid-19-cross-sectional-study-49079https://curecurrent.com/trials/coronavirus-covid-19-outcomes-registries-in-immunocompromised-individuals-australia-coria-49080https://curecurrent.com/trials/social-cognition-in-children-treated-for-a-brain-tumour-49081https://curecurrent.com/trials/clinical-evaluation-of-genetron-lung-cancer-panel-in-non-small-cell-lung-cancer-patients-49082https://curecurrent.com/trials/comparison-of-energy-instruments-and-stapling-device-to-dissect-intersegmental-plane-in-segmentectomy-49083https://curecurrent.com/trials/a-dose-exploration-study-of-almonertinib-for-egfrm-nsclc-patients-with-brain-leptomeningeal-metastasis-artistry-49084https://curecurrent.com/trials/trial-of-identifying-the-lung-intersegmental-plane-by-iron-sucrose-injection-staining-49085https://curecurrent.com/trials/safety-and-feasibility-of-pulmonary-surgery-marker-system-in-the-intraoperative-localization-of-small-pulmonary-nodules-49086https://curecurrent.com/trials/practical-usability-of-egfr-mutation-detection-in-ctdna-from-resectable-nsclc-49087https://curecurrent.com/trials/apg-1252-in-patients-with-sclc-or-advanced-solid-tumors-49088https://curecurrent.com/trials/combination-chemotherapy-radiation-therapy-and-rsr13-in-treating-patients-with-stage-iii-non-small-cell-lung-cancer-49089https://curecurrent.com/trials/a-window-of-opportunity-study-for-investigating-drug-tolerant-persister-dtp-to-neoadjuvant-osimertinib-in-resectable-non-49090https://curecurrent.com/trials/randomized-study-of-preoperative-dexamethasone-for-quality-of-recovery-in-vats-lung-resection-patients-49091https://curecurrent.com/trials/progressive-web-app-about-individualized-patient-decision-aid-for-nsclc-stage-i-ii-49092https://curecurrent.com/trials/dynamic-pet-ct-evaluated-the-response-of-neoadjuvant-anti-pd1-combination-with-chemotherapy-for-a-b-nsclc-49093https://curecurrent.com/trials/surgery-versus-stereotactic-body-radiation-therapy-for-stage-up-to-ia2-t1a-or-t1b-non-small-cell-lung-cancer-49094https://curecurrent.com/trials/immunotherapy-in-lung-cancer-treatment-after-io-cessation-49095https://curecurrent.com/trials/kinetics-of-circulating-tumoral-cells-in-bronchial-primitive-cancer-49096https://curecurrent.com/trials/cardiovascular-morbidities-and-lung-cancer-treatment-a-prospective-registry-49097https://curecurrent.com/trials/prognostic-role-of-primary-non-small-cell-lung-carcinoma-standardized-f18-fdg-uptake-values-suv-and-tlg-measured-with-f1-49098https://curecurrent.com/trials/inetetamab-in-combination-with-pyrotinib-in-her2-mutant-or-amplified-advanced-non-small-cell-lung-cancer-49099https://curecurrent.com/trials/has-inflammation-a-significant-implication-in-lung-cancer-evolution-49100https://curecurrent.com/trials/alta-1l-study-a-study-of-brigatinib-versus-crizotinib-in-anaplastic-lymphoma-kinase-positive-alk-advanced-non-small-cell-49101https://curecurrent.com/trials/a-clinical-study-of-tqb2450-injection-combined-with-anlotinib-hydrochloride-capsules-versus-k-drug-in-the-treatment-of-f-49102https://curecurrent.com/trials/proton-therapy-to-reduce-acute-normal-tissue-toxicity-in-locally-advanced-non-small-cell-lung-cancer-49103https://curecurrent.com/trials/phase-i-study-of-milatuzumab-for-graft-versus-host-disease-49104https://curecurrent.com/trials/clinical-and-immunological-evolution-of-covid-19-occurring-in-a-context-of-non-hodgkin-lymphoma-49105https://curecurrent.com/trials/a-safety-and-tolerability-study-of-nc318-in-combination-with-chemotherapy-for-subjects-with-advanced-or-metastatic-nsclc-49106https://curecurrent.com/trials/pemetrexed-disodium-observation-in-treating-patients-w-malignant-pleural-mesothelioma-w-out-progressive-disease-after-1s-49107https://curecurrent.com/trials/identify-prognostic-biomarkers-of-lung-cancer-49108https://curecurrent.com/trials/studying-biomarkers-in-tumor-tissue-and-blood-samples-from-patients-with-small-cell-lung-cancer-registered-on-calgb-1402-49109https://curecurrent.com/trials/gut-microbiota-reconstruction-for-nsclc-immunotherapy-49110https://curecurrent.com/trials/studying-tumor-tissue-samples-from-patients-with-early-stage-non-small-cell-lung-cancer-49111https://curecurrent.com/trials/a-study-to-evaluate-the-safety-tolerability-pharmacokinetics-and-preliminary-anti-tumor-activity-of-the-oral-anaplastic-49112https://curecurrent.com/trials/changing-of-prostate-specific-antigen-value-in-patients-with-covid-19-49113https://curecurrent.com/trials/a-phase-ib-trial-to-evaluate-the-safety-and-efficacy-of-fmt-and-nivolumab-in-subjects-with-metastatic-or-inoperable-mela-49114https://curecurrent.com/trials/rehabilitation-for-thoracoscopic-lobectomy-49115https://curecurrent.com/trials/study-of-azd9291-in-nsclc-patients-harboring-t790m-mutation-who-failed-egfr-tki-and-with-brain-and-or-lms-49116https://curecurrent.com/trials/a-phase-ii-trial-of-camrelizumab-combined-with-famitinib-for-adjuvant-treatment-of-stage-ii-iiia-nsclc-49117https://curecurrent.com/trials/pre-approval-access-program-paap-for-pralsetinib-blu-667-in-patients-with-unresectable-or-metastatic-nsclc-or-mtc-49118https://curecurrent.com/trials/a-study-of-abemaciclib-ly2835219-in-participants-with-stage-iv-squamous-non-small-cell-lung-cancer-49119https://curecurrent.com/trials/effect-of-preoperative-oral-carbohydrate-administration-in-thoracic-surgery-patients-49120https://curecurrent.com/trials/gut-microbiota-and-cancer-immunotherapy-response-49121https://curecurrent.com/trials/ctc-in-lung-caner-patients-with-bone-metastases-49122https://curecurrent.com/trials/sintilimab-anlotinib-hydrochloride-and-platinum-containing-dual-agent-chemotherapy-in-nsclc-49123https://curecurrent.com/trials/physical-activity-intervention-before-and-after-surgery-in-older-adults-with-lung-cancer-and-their-family-caregivers-49124https://curecurrent.com/trials/chemotherapy-combined-with-camrelizumab-and-apatinib-in-first-line-treatment-of-es-sclc-49125https://curecurrent.com/trials/frame-001-personalized-vaccine-in-nsclc-49126https://curecurrent.com/trials/radvax-a-stratified-phase-i-ii-dose-escalation-trial-of-hypofractionated-radiotherapy-followed-by-ipilimumab-in-metastat-49127https://curecurrent.com/trials/external-control-observational-retrospective-study-comparing-pralsetinib-to-best-available-therapy-in-patients-with-ret-49128https://curecurrent.com/trials/beta-glucan-in-treating-patients-with-locally-advanced-or-metastatic-non-small-cell-lung-cancer-49129https://curecurrent.com/trials/nintedanib-vargatef-plus-docetaxel-in-second-line-of-treatment-in-patients-with-lung-cancer-49130https://curecurrent.com/trials/a-study-of-atezolizumab-in-combination-with-carboplatin-plus-nab-paclitaxel-compared-with-carboplatin-nab-paclitaxel-in-49131https://curecurrent.com/trials/epidemiological-study-to-assess-the-prevalence-of-lung-cancer-49132https://curecurrent.com/trials/trial-of-belotecan-cisplatin-in-chemotherapy-naive-small-cell-lung-cancer-patient-49133https://curecurrent.com/trials/combined-simvastatin-and-irinotecan-in-treating-es-sclc-patients-relapsed-from-1st-chemotherapy-49134https://curecurrent.com/trials/efficacy-and-safety-of-adjuvant-pemetrexed-plus-cisplatin-for-adenocarcinoma-of-lung-49135https://curecurrent.com/trials/a-study-to-evaluate-the-safety-of-concurrent-durvalumab-with-crt-followed-by-durvalumab-for-chinese-unresectable-stage-i-49136https://curecurrent.com/trials/a-study-of-ly3295668-erbumine-in-participants-with-extensive-stage-small-cell-lung-cancer-49137https://curecurrent.com/trials/everolimus-plus-best-supportive-care-vs-placebo-plus-best-supportive-care-in-the-treatment-of-patients-with-advanced-neu-49138https://curecurrent.com/trials/immune-checkpoint-inhibitors-in-advanced-non-small-cell-lung-cancer-and-discovery-of-new-biomarkers-49139https://curecurrent.com/trials/clinical-utility-assay-as-a-biomarker-for-gastroenteropancreatic-and-lung-neuroendocrine-tumors-49140https://curecurrent.com/trials/adoptive-tkc-transfer-combined-with-chemotherapy-for-advanced-non-small-cell-lung-cancer-nsclc-49141https://curecurrent.com/trials/post-covid-19-pulmonary-rehabilitation-program-49142https://curecurrent.com/trials/osimertinib-in-first-and-second-line-treatment-of-nsclc-harboring-egfr-mutations-from-circulating-tumor-dna-49143https://curecurrent.com/trials/chips-vte-study-in-hospitalized-patients-with-lung-cancer-49144https://curecurrent.com/trials/a-prospective-observational-study-evaluating-c-met-expression-and-egfr-gene-mutation-correlation-with-erlotinib-response-49145https://curecurrent.com/trials/effect-of-two-different-preoperative-training-densities-in-patients-with-non-small-cell-lung-cancer-before-lung-resectio-49146https://curecurrent.com/trials/adjuvant-melatonin-for-prevention-of-lung-cancer-recurrence-and-mortality-49147https://curecurrent.com/trials/a-study-on-the-safety-and-tolerability-of-rovalpituzumab-tesirine-in-japanese-patients-with-advanced-recurrent-small-cel-49148https://curecurrent.com/trials/ilas-in-ct-lung-cancer-screening-population-49149https://curecurrent.com/trials/evaluation-of-nsclc-patients-oxygen-uptake-on-kinetics-at-cycle-ergometer-during-prehabilitation-49150https://curecurrent.com/trials/osimertinib-plus-bevacizumab-in-untreated-egfr-exon21-l858r-mutated-nsclc-49151https://curecurrent.com/trials/evaluation-of-the-effect-and-side-effect-profile-of-covid-19-vaccine-in-cancer-patients-49152https://curecurrent.com/trials/afatinib-in-lung-cancer-with-egfr-mutation-from-circulating-tumor-dna-49153https://curecurrent.com/trials/impact-of-pulmonary-rehabilitation-after-lung-resection-for-cancer-on-patients-level-of-anxiety-and-depression-49154https://curecurrent.com/trials/avoiding-cardiac-toxicity-in-lung-cancer-patients-treated-with-curative-intent-radiotherapy-49155https://curecurrent.com/trials/memory-preservation-of-prophylactic-cranial-irradiation-with-hippocampal-avoidance-premer-trial-49156https://curecurrent.com/trials/heuristics-algorithms-and-machine-learning-evaluation-testing-in-radiation-therapy-49157https://curecurrent.com/trials/role-of-helicobacter-pylori-and-its-toxins-in-lung-and-digestive-system-diseases-49158https://curecurrent.com/trials/study-of-rovalpituzumab-tesirine-sc16ld6-5-for-third-line-and-later-treatment-of-subjects-with-relapsed-or-refractory-de-49159https://curecurrent.com/trials/ctdna-dynamic-monitoring-and-its-role-of-prognosis-in-stage-ii-to-iiia-nsclc-by-ngs-49160https://curecurrent.com/trials/combined-simvastatin-and-albumin-paclitaxel-in-treating-es-sclc-patients-relapsed-from-1st-chemotherapy-49161https://curecurrent.com/trials/a-study-of-rovalpituzumab-tesirine-as-maintenance-therapy-following-first-line-platinum-based-chemotherapy-in-participan-49162https://curecurrent.com/trials/covid-19-pandemic-impact-on-patients-with-cancer-a-danish-survey-49163https://curecurrent.com/trials/pembrolizumab-in-combination-with-radiotherapy-in-locally-advanced-non-small-cell-lung-cancer-nsclc-49164https://curecurrent.com/trials/a-phase-ii-study-of-sintilimab-combined-with-anlotinib-in-treatment-of-ed-sclc-49165https://curecurrent.com/trials/effectiveness-of-mrna-covid-19-vaccines-on-cancer-patients-observational-study-anticov-49166https://curecurrent.com/trials/multi-dimensional-signatures-for-precisely-predicting-the-response-and-prognosis-of-lung-cancer-patients-49167https://curecurrent.com/trials/the-efficacy-and-safety-of-anlotinib-combined-with-almonertinib-in-the-first-line-treatment-of-patients-with-brain-metas-49168https://curecurrent.com/trials/study-of-shr-1701-plus-bp102-in-subjects-with-selected-solid-tumors-49169https://curecurrent.com/trials/radiation-induced-cardiac-toxicity-after-non-small-cell-lung-cancer-radiotherapy-49170https://curecurrent.com/trials/covid-19-and-reorganisation-of-cancer-patient-care-self-evaluation-of-potential-post-traumatic-stress-disorder-49171https://curecurrent.com/trials/coagulation-system-in-stereotactic-radiotherapy-of-nsclc-49172https://curecurrent.com/trials/feasibility-study-incorporating-lung-function-imaging-into-radiation-therapy-for-lung-cancer-patients-49173https://curecurrent.com/trials/camrelizumab-combined-with-pemetrexed-and-carboplatin-for-the-study-of-egfr-mutated-lung-squamous-nsclc-treatment-49174https://curecurrent.com/trials/a-study-of-furmonertinib-combined-with-radiotherapy-for-non-small-cell-lung-cancer-with-oligoprogression-49175https://curecurrent.com/trials/isolating-and-testing-circulating-tumor-dna-and-soluble-immune-markers-during-the-course-of-treatment-for-lung-cancer-49176https://curecurrent.com/trials/a-study-to-evaluate-the-safety-and-anti-tumor-activity-of-snk01-nk-cells-administered-in-combination-with-chemotherapy-o-49177https://curecurrent.com/trials/study-of-cbp501-pemetrexed-cisplatin-on-mpm-phase-i-ii-49178https://curecurrent.com/trials/the-impacts-of-intermittent-chest-tube-clamping-on-chest-tube-drainage-duration-and-postoperative-hospital-stay-after-lu-49179https://curecurrent.com/trials/icotinib-as-adjuvant-therapy-compared-with-standard-chemotherapy-in-stage-ii-iiia-nsclc-with-egfr-mutation-49180https://curecurrent.com/trials/application-of-pablizumab-combined-with-apatinib-and-chemotherapy-in-resectable-non-small-cell-lung-cancer-a-prospective-49181https://curecurrent.com/trials/study-of-cryoablation-for-metastatic-lung-tumors-49182https://curecurrent.com/trials/pf-06463922-for-crizotinib-pretreated-ros1-positive-non-small-cell-lung-cancer-49183https://curecurrent.com/trials/safety-and-efficacy-of-cryoablation-for-metastatic-lung-tumors-49184https://curecurrent.com/trials/furmonertinib-as-perioperation-therapy-in-stage-iiia-iiib-n1-n2-resectable-egfr-mutated-lung-adenocarcinoma-front-49185https://curecurrent.com/trials/paclitaxel-albumin-stabilized-nanoparticle-formulation-in-treating-patients-with-previously-treated-advanced-non-small-c-49186https://curecurrent.com/trials/neomend-progel-pleural-air-leak-sealant-post-approval-study-49187https://curecurrent.com/trials/retreatment-with-epidermal-growth-factor-receptor-egfr-tyrosine-kinase-inhibitor-in-egfr-mutation-positive-patients-49188https://curecurrent.com/trials/binimetinib-in-addition-to-standard-chemotherapy-in-kras-mutated-nsclc-49189https://curecurrent.com/trials/idylla-egfr-lung-trial-49190https://curecurrent.com/trials/impact-of-measures-taken-to-contain-covid-19-on-hospital-surgical-care-services-and-clinical-outcomes-49191https://curecurrent.com/trials/pembrolizumab-in-treating-patients-with-egfr-mutant-tyrosine-kinase-inhibitor-naive-advanced-non-small-cell-lung-cancer-49192https://curecurrent.com/trials/lurbinectedin-monotherapy-in-patients-with-progressive-malignant-pleural-mesothelioma-49193https://curecurrent.com/trials/study-to-investigate-safety-pharmacokinetic-pk-pharmacodynamic-pd-and-clinical-activity-of-trametinib-in-subjects-with-c-49194https://curecurrent.com/trials/dexamethasone-flurbiprofen-axetil-and-delirium-after-lung-cancer-surgery-49195https://curecurrent.com/trials/olanzapine-for-the-prevention-and-treatment-of-nausea-and-vomiting-induced-by-chemotherapy-of-lung-cancer-49196https://curecurrent.com/trials/investigation-of-the-anti-cancer-activity-of-artichoke-extract-in-an-asbestos-exposed-population-49197https://curecurrent.com/trials/initiative-in-lyon-for-lung-cancer-screening-development-prevalence-study-49198https://curecurrent.com/trials/study-to-assess-the-effect-of-rifampicin-on-blood-levels-and-safety-of-azd9291-in-patients-with-egfrm-nsclc-49199https://curecurrent.com/trials/ultralow-dose-ct-for-lung-cancer-screening-49200https://curecurrent.com/trials/satisfaction-and-quality-of-life-comparison-between-patients-using-cicaplast-baume-b5-versus-dexeryl-for-the-management-49201https://curecurrent.com/trials/a-phase-i-ii-clinical-study-of-saf-189s-in-non-small-cell-lung-cancer-nsclc-patients-49202https://curecurrent.com/trials/predicting-cell-death-by-radiation-therapy-in-early-stage-non-small-cell-lung-cancer-a-prospective-translational-trial-49203https://curecurrent.com/trials/effect-of-tumor-treating-fields-ttfields-150-khz-concomitant-with-best-standard-of-care-for-the-treatment-of-hospitalize-49204https://curecurrent.com/trials/proton-beam-radiation-with-concurrent-chemotherapy-and-nelfinavir-for-inoperable-stage-iii-non-small-cell-lung-cancer-ns-49205https://curecurrent.com/trials/combination-of-almonertinib-and-concurrent-chemoradiotherapy-in-unresectable-stage-iii-nsclc-49206https://curecurrent.com/trials/a-phase-iii-study-to-assess-the-efficacy-and-safety-of-almonertinib-versus-platinum-based-chemotherapy-as-first-line-the-49207https://curecurrent.com/trials/pembrolizumab-cva21-in-advanced-nsclc-49208https://curecurrent.com/trials/a-study-of-camrelizumab-combined-with-chemotherapy-sequential-camrelizumab-combined-with-apatinib-treatment-of-advanced-49209https://curecurrent.com/trials/implementation-of-adjuvants-in-intercostal-nerve-blockades-for-thoracoscopic-surgery-in-pulmonary-cancer-patients-49210https://curecurrent.com/trials/pk-study-for-endostar-continuous-intravenous-infusion-in-nsclc-patients-with-1st-line-platinum-based-chemotherapy-49211https://curecurrent.com/trials/neoadjuvant-immune-checkpoint-inhibitor-combined-with-chemotherapy-in-non-small-cell-lung-cancer-49212https://curecurrent.com/trials/whole-lung-imrt-in-children-and-adults-with-synovial-sarcoma-and-lung-metastases-49213https://curecurrent.com/trials/almonertinib-with-bevacizumab-for-egfr-mutant-nsclc-patients-with-leptomeningeal-metastasis-49214https://curecurrent.com/trials/neoadjuvant-immunotherapy-with-chemotherapy-for-stage-i-iiib-non-small-cell-lung-cancer-patients-49215https://curecurrent.com/trials/a-study-of-trc105-in-combination-with-paclitaxel-carboplatin-and-bevacizumab-in-non-squamous-cell-lung-cancer-49216https://curecurrent.com/trials/effect-of-trimetazidine-on-radiotherapy-induced-heart-damage-49217https://curecurrent.com/trials/tumor-mutational-burden-in-lung-cancer-patients-49218https://curecurrent.com/trials/lung-map-talazoparib-in-treating-patients-with-hrrd-positive-recurrent-stage-iv-squamous-cell-lung-cancer-49219https://curecurrent.com/trials/an-alternative-radiation-fractionation-strategy-for-locally-advanced-non-small-cell-lung-cancer-nsclc-49220https://curecurrent.com/trials/neoadjuvant-camrelizumab-nab-paclitaxel-and-carboplatin-in-stage-ib-iiia-nsclc-49221https://curecurrent.com/trials/vbn-ebus-gs-tblb-with-or-without-fluoroscopy-for-the-diagnosis-of-ppls-49222https://curecurrent.com/trials/study-of-pembrolizumab-mk-3475-monotherapy-in-advanced-solid-tumors-and-pembrolizumab-combination-therapy-in-advanced-no-49223https://curecurrent.com/trials/tremelimumab-and-durvalumab-with-or-without-radiation-therapy-in-patients-with-relapsed-small-cell-lung-cancer-49224https://curecurrent.com/trials/a-feasibility-study-using-four-dimensional-ct-imaging-for-primary-lung-cancer-49225https://curecurrent.com/trials/fluzopalil-in-combination-with-anlotinib-for-extensive-small-cell-lung-cancer-49226https://curecurrent.com/trials/comparison-of-genomic-and-transcriptomic-patterns-between-ctc-and-metastatic-tumormetastatic-tumor-49227https://curecurrent.com/trials/a-multicentre-study-of-intraoperative-body-temperature-changes-in-patients-undergoing-thoracoscopic-radical-surgery-for-49228https://curecurrent.com/trials/a-micro-nano-device-for-exhaled-breath-analysis-49229https://curecurrent.com/trials/systematic-symptom-assessment-in-cancer-patients-treated-with-immune-checkpoint-inhibitors-49230https://curecurrent.com/trials/design-and-evaluation-of-a-novel-methodology-for-sabr-for-lung-cancer-49231https://curecurrent.com/trials/additive-homeopathy-in-cancer-patients-49232https://curecurrent.com/trials/a-study-evaluating-the-efficacy-and-safety-of-adjuvant-platinum-doublet-chemotherapy-with-or-without-atezolizumab-in-pat-49233https://curecurrent.com/trials/study-of-erlotinib-with-or-without-investigational-drug-u3-1287-in-subjects-with-advanced-non-small-cell-lung-cancer-49234https://curecurrent.com/trials/radiation-therapy-in-treating-patients-with-stage-i-or-stage-ii-non-small-cell-lung-cancer-49235https://curecurrent.com/trials/investigation-of-the-effectiveness-of-coronavac-vaccine-in-cancer-patients-with-active-chemotherapy-and-comparison-with-49236https://curecurrent.com/trials/lung-nodule-imaging-biobank-for-radiomics-and-ai-research-49237https://curecurrent.com/trials/study-for-patients-with-nsclc-egfr-mutations-del-19-or-l858r-t790m-49238https://curecurrent.com/trials/a-study-to-testabi-009-in-patients-with-metastatic-unresectable-low-or-intermediate-grade-neuroendocrine-tumors-of-the-l-49239https://curecurrent.com/trials/pembrolizumab-in-first-line-treatment-of-advanced-nsclc-patients-with-pd-l1-low-tumors-49240https://curecurrent.com/trials/immunological-markers-predictive-of-response-and-toxicity-to-checkpoint-inhibitors-in-non-small-cell-lung-cancer-49241https://curecurrent.com/trials/assessment-of-2-different-techniques-for-suppression-of-respiratory-motion-in-lung-cancer-treatment-with-proton-therapy-49242https://curecurrent.com/trials/an-exploratory-clinical-study-of-tils-in-the-treatment-of-recurrent-refractory-non-small-cell-lung-cancer-nsclc-49243https://curecurrent.com/trials/dietary-flaxseed-in-nsclc-49244https://curecurrent.com/trials/covid-19-study-of-immune-responses-following-vaccination-against-sars-cov-2-49245https://curecurrent.com/trials/the-metnet-2-trial-49246https://curecurrent.com/trials/effects-of-different-physical-therapy-programs-on-pulmonary-rehabilitation-in-patients-with-lung-cancer-49247https://curecurrent.com/trials/stereotactic-radiosurgery-combination-with-anlotinib-for-limited-brain-metastases-in-nsclc-49248https://curecurrent.com/trials/osimertinib-study-in-indian-patients-49249https://curecurrent.com/trials/sorafenib-with-capecitabine-for-patients-with-measurable-hepatocellular-carcinoma-49250https://curecurrent.com/trials/medical-treatment-of-solid-tumors-at-the-lyon-university-hospital-cancer-institute-during-the-first-wave-of-covid-19-in-49251https://curecurrent.com/trials/pre-operative-gefitinib-in-resectable-egfr-mutation-positive-lung-cancer-with-sector-sequencing-for-biomarker-discovery-49252https://curecurrent.com/trials/convalescent-plasma-as-adjunct-therapy-for-covid-19-49253https://curecurrent.com/trials/cisplatin-and-etoposide-plus-radiation-followed-by-nivolumab-placebo-for-locally-advanced-nsclc-49254https://curecurrent.com/trials/almonertinib-combined-with-cerebral-radiation-treat-brain-metastases-from-egfr-positive-nsclc-49255https://curecurrent.com/trials/effect-of-multi-modal-intervention-care-on-cachexia-in-patients-with-advanced-cancer-compared-to-conventional-management-49256https://curecurrent.com/trials/the-influence-of-cancer-stem-cells-on-risk-of-relapse-in-patients-harboring-adenocarcinoma-and-squamous-cell-carcinoma-o-49257https://curecurrent.com/trials/lung-cancer-patients-attitudes-to-a-second-course-of-radiotherapy-49258https://curecurrent.com/trials/locally-advanced-nsclc-hyperfractionated-rt-49259https://curecurrent.com/trials/lung-map-palbociclib-as-second-line-therapy-in-treating-cell-cycle-gene-alteration-positive-patients-with-recurrent-stag-49260https://curecurrent.com/trials/panorama-real-world-molecular-testing-treatment-patterns-and-clinical-outcomes-egfr-mutation-positive-nsclc-49261https://curecurrent.com/trials/lung-map-azd4547-as-second-line-therapy-in-treating-fgfr-positive-patients-with-recurrent-stage-iv-squamous-cell-lung-ca-49262https://curecurrent.com/trials/a-prospective-two-center-single-arm-phase-ii-clinical-study-to-evaluate-safety-and-effectiveness-of-ablation-therapy-in-49263https://curecurrent.com/trials/pemetrexed-in-maintenance-in-patients-with-impaired-renal-function-2-dose-calculation-strategies-49264https://curecurrent.com/trials/phase-ii-study-of-stereotactic-body-radiation-therapy-using-tomotherapy-for-tumors-of-the-lung-49265https://curecurrent.com/trials/pt-cy-with-or-without-low-dose-atg-for-lymphoid-malignancies-undergoing-allo-hsct-49266https://curecurrent.com/trials/phase-1b-trial-of-lenvatinib-plus-pembrolizumab-in-participants-with-selected-solid-tumors-49267https://curecurrent.com/trials/adaptive-ct-acquisition-for-personalised-thoracic-imaging-49268https://curecurrent.com/trials/safety-and-effectiveness-of-disposable-pulmonary-surgical-markers-in-the-localization-of-pulmonary-nodules-49269https://curecurrent.com/trials/gsk3174998-alone-and-with-pembrolizumab-in-participants-with-advanced-solid-tumors-engage-1-49270https://curecurrent.com/trials/a-phase-ib-iia-study-of-al8326-in-small-cell-lung-cancer-49271https://curecurrent.com/trials/a-multicenter-phase-3-open-label-study-of-bosutinib-versus-imatinib-in-adult-patients-with-newly-diagnosed-chronic-phase-49272https://curecurrent.com/trials/aprepitant-vs-desloratadine-in-egfr-tkis-related-pruritus-treatment-49273https://curecurrent.com/trials/proton-beam-radiation-therapy-and-chemotherapy-in-treating-patients-with-stage-iii-non-small-cell-lung-cancer-that-can-b-49274https://curecurrent.com/trials/a-trial-of-camrelizumab-combined-with-microwave-ablation-and-chemotherapy-in-the-treatment-of-colorectal-cancer-liver-me-49275https://curecurrent.com/trials/immune-and-microenvironment-proteogenomics-profiling-for-classifying-lung-cancer-patients-49276https://curecurrent.com/trials/cs-7017-in-combination-with-erlotinib-in-subjects-with-stage-iiib-iv-non-small-cell-lung-cancer-nsclc-49277https://curecurrent.com/trials/study-of-collagen-iv-and-xix-in-bronchoalveolar-lavage-pulmonary-aspiration-and-bronchial-biopsies-49278https://curecurrent.com/trials/a-study-of-atezolizumab-in-unresectable-or-advaced-malignant-pleural-mesothelioma-49279https://curecurrent.com/trials/a-study-of-enzastaurin-and-erlotinib-in-participants-with-solid-tumors-and-lung-cancer-49280https://curecurrent.com/trials/first-line-chemotherapy-treatment-of-advanced-non-small-cell-lung-cancer-nsclc-49281https://curecurrent.com/trials/study-of-pemetrexed-carboplatin-bevacizumab-enzastaurin-versus-pemetrexed-carboplatin-bevacizumab-placebo-in-participant-49282https://curecurrent.com/trials/a-trial-of-shr-1701-in-combination-with-and-without-famitinib-malate-in-patients-with-extensive-stage-small-cell-lung-ca-49283https://curecurrent.com/trials/serial-18f-thymidine-flt-pet-ct-as-a-biomarker-of-response-in-pemetrexed-therapy-for-non-small-cell-lung-cancer-49284https://curecurrent.com/trials/a-case-cohort-study-of-hematopoietic-malignancies-and-related-disorders-and-lung-cancer-in-benzene-exposed-workers-in-ch-49285https://curecurrent.com/trials/a-study-of-tl-895-with-standard-available-treatment-versus-standard-available-treatment-for-the-treatment-of-covid-19-in-49286https://curecurrent.com/trials/chemotherapy-combined-autologous-cytokine-induced-killer-cells-in-naive-stage-iv-egfr-wild-type-lung-adenocarcinoma-49287https://curecurrent.com/trials/energy-for-lymphocytes-49288https://curecurrent.com/trials/cell-free-dna-for-the-diagnosis-and-treatment-in-early-nsclc-49289https://curecurrent.com/trials/concurrent-chemoradiotherapy-combination-with-anlotinib-for-limited-stage-small-cell-lung-cancer-49290https://curecurrent.com/trials/effect-of-thyrotropin-level-on-iodine-uptake-in-metastatic-differentiated-thyroid-cancer-49291https://curecurrent.com/trials/feasibility-of-tracheobronchial-reconstruction-using-bioengineered-aortic-matrices-49292https://curecurrent.com/trials/fluzoparib-combined-with-camrelizumab-for-maintenance-treatment-of-locally-advanced-non-small-cell-lung-cancer-49293https://curecurrent.com/trials/almonertinib-treats-advanced-nsclc-patients-with-egfr-mutations-who-are-safety-intolerant-after-osimertinib-treatment-49294https://curecurrent.com/trials/jy025-is-a-first-line-treatment-for-egfr-mutated-nsclc-phase-ii-and-iii-clinical-trials-of-efficacy-and-safety-49295https://curecurrent.com/trials/evaluation-of-a-cosmetic-product-to-preserve-skin-conditions-when-using-anti-egfr-cancer-therapies-49296https://curecurrent.com/trials/coaxial-drainage-versus-standard-chest-tube-after-pulmonary-lobectomy-49297https://curecurrent.com/trials/vats-versus-open-pulmonary-lobectomy-in-the-limelight-of-oep-49298https://curecurrent.com/trials/dose-escalation-pan-fgfr-fibroblast-growth-factor-receptor-inhibitor-rogaratinib-49299https://curecurrent.com/trials/team-based-versus-primary-care-clinician-led-advance-care-planning-in-practice-based-research-networks-49300https://curecurrent.com/trials/clinical-study-of-cd276-targeted-autologous-chimeric-antigen-receptor-t-cell-infusion-in-patients-with-cd276-positive-ad-49301https://curecurrent.com/trials/a-study-evaluating-the-safety-pharmacokinetics-and-anti-tumor-activity-of-abbv-321-in-subjects-with-advanced-solid-tumor-49302https://curecurrent.com/trials/a-study-of-nivolumab-in-advanced-non-small-cell-lung-cancer-nsclc-49303https://curecurrent.com/trials/the-utility-of-pet-ct-in-the-planning-of-stereotactic-body-radiotherapy-for-non-small-cell-lung-cancer-49304https://curecurrent.com/trials/neoadjuvant-toripalimab-plus-platinum-based-doublet-for-stage-iii-non-small-cell-lung-cancer-49305https://curecurrent.com/trials/characterization-of-methylation-patterns-in-lung-cancer-49306https://curecurrent.com/trials/phase-i-study-of-accelerated-hypofractionated-image-guided-radiation-therapy-49307https://curecurrent.com/trials/tocotrienol-as-a-nutritional-supplement-in-patients-with-advanced-lung-cancer-49308https://curecurrent.com/trials/noninvasive-vs-invasive-lung-evaluation-49309https://curecurrent.com/trials/neoadjuvant-itraconazole-in-non-small-cell-lung-cancer-49310https://curecurrent.com/trials/stereotactic-body-radiotherapy-sbrt-for-pulmonary-metastases-in-ewing-sarcoma-rhabdomyosarcoma-and-wilms-tumors-49311https://curecurrent.com/trials/study-of-recombinant-human-anti-pd-1-monoclonal-antibody-in-patients-with-advanced-tumours-49312https://curecurrent.com/trials/efficacy-and-safety-of-prophylactic-cranial-irradiation-versus-mri-surveillance-in-patients-with-limited-stage-small-cel-49313https://curecurrent.com/trials/neoadjuvant-chemotherapy-and-tilelizumab-in-stage-iii-ctnm-iiia-iiib-non-small-cell-lung-cancer-49314https://curecurrent.com/trials/accelerated-hypofractionated-vs-conventionally-fractionated-concurrent-crt-for-ls-sclc-49315https://curecurrent.com/trials/targeted-stem-cells-expressing-trail-as-a-therapy-for-lung-cancer-49316https://curecurrent.com/trials/antineoplaston-therapy-in-treating-patients-with-advanced-mesothelioma-49317https://curecurrent.com/trials/open-label-uncontrolled-non-interventional-retrospective-study-to-evaluate-molecular-determinants-of-outcome-to-the-immu-49318https://curecurrent.com/trials/investigation-on-predictive-molecular-markers-of-efficacy-for-front-line-immunochemotherapy-in-advanced-nsclc-49319https://curecurrent.com/trials/a-study-comparing-mb02-and-avastin-in-subjects-with-stage-iiib-iv-non-squamous-non-small-cell-lung-cancer-nsclc-49320https://curecurrent.com/trials/real-life-second-line-nivolumab-in-advanced-non-small-cell-lung-cancer-49321https://curecurrent.com/trials/routine-electronic-monitoring-of-quality-of-life-poumon-remoqol-poumon-49322https://curecurrent.com/trials/open-label-phase-ii-study-to-evaluate-efficacy-and-safety-of-oral-nilotinib-in-philadelphia-positive-ph-chronic-myelogen-49323https://curecurrent.com/trials/a-neoadjuvant-study-of-sintilimab-plus-platinum-doublet-chemotherapy-in-iiia-n2-stage-nsclc-49324https://curecurrent.com/trials/clinical-efficacy-and-safety-of-egfr-tki-combined-with-nimotuzumab-in-the-treatment-of-leptomeningeal-metastases-from-lu-49325https://curecurrent.com/trials/cardiopulmonary-fitness-and-its-clinical-determinants-of-a-population-of-childhood-cancer-survivor-49326https://curecurrent.com/trials/a-study-of-nivolumab-and-intrapleural-talimogene-laherparepvec-for-malignant-pleural-effusion-49327https://curecurrent.com/trials/a-pilot-study-to-develop-predictive-biomarkers-for-the-response-to-immunotherapy-in-lung-cancer-49328https://curecurrent.com/trials/penpulimab-based-combination-neoadjuvant-adjuvant-therapy-for-patients-with-resectable-locally-advanced-non-small-cell-l-49329https://curecurrent.com/trials/prone-positioning-in-non-intubated-patients-with-covid-19-associated-acute-respiratory-failure-49330https://curecurrent.com/trials/pemetrexed-disodium-gemcitabine-and-bevacizumab-in-treating-patients-with-stage-iiib-or-stage-iv-non-small-cell-lung-can-49331https://curecurrent.com/trials/study-of-pazopanib-in-the-treatment-of-osteosarcoma-metastatic-to-the-lung-49332https://curecurrent.com/trials/stereotactic-ablation-radiotherapy-combined-with-sintilimab-in-early-inoperable-synchronous-multiple-primary-lung-cancer-49333https://curecurrent.com/trials/drug-eluting-beads-bronchial-arterial-chemoembolization-in-stage-ii-iii-non-small-cell-lung-cancer-patients-failed-refus-49334https://curecurrent.com/trials/capillary-versus-suction-needle-aspiration-for-endobronchial-ultrasound-ebus-biopsies-49335https://curecurrent.com/trials/a-safety-and-efficacy-study-of-inc280-and-gefitinib-in-patients-with-egfr-mutated-c-met-amplified-nsclc-who-have-progres-49336https://curecurrent.com/trials/clinical-study-to-evaluate-the-maximum-tolerated-dose-of-bay1000394-when-given-together-with-chemotherapy-and-the-effect-49337https://curecurrent.com/trials/extension-study-of-ec145-vintafolide-for-subjects-enrolled-in-a-previous-study-with-ec145-mk-8109-010-49338https://curecurrent.com/trials/radiotherapy-combined-with-immunotherapy-for-brain-metastases-of-non-small-cell-lung-cancer-49339https://curecurrent.com/trials/maintenance-targeted-therapy-with-or-without-stereotactic-body-radiation-therapy-for-stage-iv-non-small-cell-lung-cancer-49340https://curecurrent.com/trials/sbrt-stereotactic-body-radiation-therapy-vs-surgery-in-high-risk-patients-with-early-stage-lung-cancer-49341https://curecurrent.com/trials/lung-cancer-screening-protocol-49342https://curecurrent.com/trials/tisotumab-vedotin-humax-tf-adc-safety-study-in-patients-with-solid-tumors-49343https://curecurrent.com/trials/tivantinib-plus-erlotinib-versus-placebo-plus-erlotinib-for-the-treatment-of-non-squamous-non-small-cell-lung-cancer-49344https://curecurrent.com/trials/impact-of-pd1-lymphocytes-in-bronchoalveolar-lavage-of-patients-with-lung-cancer-49345https://curecurrent.com/trials/toripalimab-combined-with-bevacizumab-nab-paclitaxel-and-carboplatin-for-untreated-metastatic-pulmonary-sarcomatoid-carc-49346https://curecurrent.com/trials/phase-1-2-study-of-mocetinostat-and-durvalumab-in-patients-with-advanced-solid-tumors-and-nsclc-49347https://curecurrent.com/trials/neurocognition-in-nsclc-patients-treated-with-osimertinib-or-osimertinib-wbi-49348https://curecurrent.com/trials/3-arm-trial-to-evaluate-pasireotide-lar-everolimus-alone-in-combination-in-patients-with-lung-thymus-net-luna-trial-49349https://curecurrent.com/trials/phase-2-study-of-ec145-alone-versus-ec145-docetaxel-versus-docetaxel-alone-in-participants-with-fr-2nd-line-non-small-ce-49350https://curecurrent.com/trials/to-evaluate-the-efficacy-of-afatinib-in-the-treatment-of-locally-advanced-metastatic-non-small-cell-lung-cancer-with-nrg-49351https://curecurrent.com/trials/cdc1-prognostic-and-predictive-role-in-non-small-cell-lung-cancer-patients-receiving-immune-checkpoint-inhibitors-49352https://curecurrent.com/trials/iressa-re-challenge-in-advanced-nsclc-egfr-mutated-patients-49353https://curecurrent.com/trials/functional-medicine-in-asthma-fast-study-49354https://curecurrent.com/trials/ldk378-in-patients-with-alk-positive-nsclc-previously-treated-with-alectinib-49355https://curecurrent.com/trials/midrix4-lung-dendritic-cell-vaccine-in-patients-with-metastatic-non-small-cell-lung-cancer-49356https://curecurrent.com/trials/thoracal-radiotherapy-and-tarceva-49357https://curecurrent.com/trials/study-on-proton-radiotherapy-of-thymic-malignancies-49358https://curecurrent.com/trials/a-study-of-cesium-131-brachytherapy-following-sub-lobar-resection-for-early-stage-non-small-cell-lung-cancer-49359https://curecurrent.com/trials/combinatory-immunotherapy-1-com-it-1-irradiation-and-pd-1-blockade-in-locally-advanced-advanced-nsclc-49360https://curecurrent.com/trials/an-integrated-digital-prom-platform-for-cancer-patients-during-the-covid-19-pandemic-49361https://curecurrent.com/trials/second-primary-lung-cancer-cohort-study-sport-49362https://curecurrent.com/trials/assessment-of-early-detection-based-on-liquid-biopsy-in-lung-cancer-ascend-lung-49363https://curecurrent.com/trials/mk-3475-in-melanoma-and-nsclc-patients-with-brain-metastases-49364https://curecurrent.com/trials/recurrence-monitoring-in-nsclc-using-circulating-tumor-dna-49365https://curecurrent.com/trials/immunity-against-severe-acute-respiratory-syndrome-coronavirus-2-disease-covid-19-in-the-oncology-outpatient-setting-49366https://curecurrent.com/trials/an-investigational-immuno-therapy-study-to-test-combination-treatments-in-patients-with-advanced-non-small-cell-lung-can-49367https://curecurrent.com/trials/adjuvant-ccrt-vs-ct-in-minimal-n2-nsclc-49368https://curecurrent.com/trials/assessment-of-the-90-day-mortality-risk-score-after-vats-lobectomy-49369https://curecurrent.com/trials/expanded-access-to-trilaciclib-for-patients-receiving-chemotherapy-for-small-cell-lung-cancer-49370https://curecurrent.com/trials/personalized-sequence-for-thoracic-esophageal-and-h-n-cancer-49371https://curecurrent.com/trials/phase-ii-single-arm-study-of-azd1775-monotherapy-in-relapsed-small-cell-lung-cancer-patients-49372https://curecurrent.com/trials/a-stepped-care-intervention-to-reduce-disparities-in-mental-health-services-among-cancer-patients-and-caregivers-49373https://curecurrent.com/trials/gilotrif-afatinib-in-advanced-non-small-cell-lung-cancer-patients-pre-treated-with-erlotinib-or-gefitinib-49374https://curecurrent.com/trials/enb-vs-conventional-bronchoscopy-with-fluoroscopy-for-safe-and-effective-biopsy-of-pulmonary-lesions-49375https://curecurrent.com/trials/a-prospective-study-of-constructing-immune-repertoire-to-monitor-the-therapeutic-effect-in-nsclc-patients-49376https://curecurrent.com/trials/dielectric-properties-of-matched-tissue-samples-from-thoracic-malignancies-and-corresponding-normal-tissues-49377https://curecurrent.com/trials/study-15-comparing-gemcitabine-carboplatin-and-hydroxychloroquine-versus-carboplatin-etoposide-therapy-alone-in-small-ce-49378https://curecurrent.com/trials/serial-18f-fluorodeoxyglucose-18f-fdg-pet-ct-as-a-biomarker-of-therapeutic-response-in-anti-pd1-pdl1-therapy-49379https://curecurrent.com/trials/a-study-of-shr-1210-in-combination-with-bp102-in-subjects-with-non-squamous-nsclc-49380https://curecurrent.com/trials/tumor-growth-rate-tgr-predicts-clinical-outcomes-for-advanced-non-small-cell-lung-cancer-undergoing-immunotherapy-49381https://curecurrent.com/trials/paclitaxel-micelles-for-injection-paclitaxel-injection-in-combination-with-cisplatin-for-first-line-therapy-of-advanced-49382https://curecurrent.com/trials/development-of-patient-tailored-guideline-of-physical-activity-for-lung-cancer-49383https://curecurrent.com/trials/nivolumab-and-177lu-dota0-tyr3-octreotate-for-patients-with-extensive-stage-small-cell-lung-cancer-49384https://curecurrent.com/trials/a-study-of-shr-1210-in-combination-with-carboplatin-paclitaxel-in-subjects-with-squamous-nsclc-49385https://curecurrent.com/trials/study-of-anlotinib-combined-with-icotinib-as-the-first-line-treatment-in-patients-with-egfr-concomitant-mutation-nsclc-49386https://curecurrent.com/trials/study-of-anlotinib-combined-with-icotinib-as-the-first-line-treatment-in-patients-with-egfr-mutation-positive-nsclc-49387https://curecurrent.com/trials/a-study-to-evaluate-the-efficacy-of-brigatinib-ap26113-in-participants-with-anaplastic-lymphoma-kinase-alk-positive-non-49388https://curecurrent.com/trials/does-coronavirus-disease-2019-covid-19-pandemic-cause-a-delay-in-the-diagnosis-of-gastric-cancer-patients-49389https://curecurrent.com/trials/efficacy-and-safety-of-camrelizumab-in-real-world-prospective-study-49390https://curecurrent.com/trials/virtual-reality-as-an-adjunct-to-management-of-pain-and-anxiety-in-palliative-care-49391https://curecurrent.com/trials/lorlatinib-combinations-in-lung-cancer-49392https://curecurrent.com/trials/trial-of-cabozantinib-xl184-in-non-small-cell-lung-cancer-with-brain-metastases-49393https://curecurrent.com/trials/effect-of-multi-media-tool-on-enrollment-in-oncology-clinical-trials-49394https://curecurrent.com/trials/a-study-of-shr1210-in-combination-with-paclitaxel-albumin-and-carboplatin-in-extensive-stage-small-cell-lung-cancer-49395https://curecurrent.com/trials/effect-of-combination-therapy-on-sclc-after-initial-treatment-failure-49396https://curecurrent.com/trials/genetics-of-egfr-epidermal-growth-factor-receptor-mutation-study-49397https://curecurrent.com/trials/the-effects-of-preoperative-bevacizumab-on-perioperative-complications-49398https://curecurrent.com/trials/a-study-of-lorlatinib-in-advanced-alk-and-ros1-rearranged-lung-cancer-with-cns-metastasis-in-the-absence-of-measurable-e-49399https://curecurrent.com/trials/alberta-lung-cancer-screening-program-49400https://curecurrent.com/trials/iraqi-trial-for-lung-cancer-screening-49401https://curecurrent.com/trials/stereotactic-radiotherapy-in-association-with-immunotherapy-for-the-treatment-of-nsclc-brain-metastases-49402https://curecurrent.com/trials/endobronchial-cryotherapy-in-management-of-mebo-in-patients-with-inoperable-nsclc-49403https://curecurrent.com/trials/lung-function-testing-in-patients-with-locally-advanced-or-metastatic-solid-tumors-49404https://curecurrent.com/trials/study-of-pralatrexate-vs-erlotinib-for-non-small-cell-lung-cancer-after-at-least-1-prior-platinum-based-treatment-49405https://curecurrent.com/trials/reducing-lung-cancer-related-anxiety-relax-49406https://curecurrent.com/trials/cyberknife-radiosurgical-treatment-of-inoperable-early-stage-non-small-cell-lung-cancer-49407https://curecurrent.com/trials/sensitivity-of-pdl-1-analysis-from-pleural-effusion-in-non-small-cell-lung-cancer-49408https://curecurrent.com/trials/the-combination-of-apatinib-and-camerlizumab-for-advanced-lung-cancer-patients-with-muti-line-therapy-49409https://curecurrent.com/trials/copdgene-lung-cancer-center-database-49410https://curecurrent.com/trials/study-of-pd-1-antibody-and-parp-inhibitor-in-extensive-stage-small-cell-lung-cancer-49411https://curecurrent.com/trials/safety-and-efficacy-of-genolimzumab-gb226-in-combination-with-fruquintinib-49412https://curecurrent.com/trials/antibodies-production-after-covid-19-vaccination-among-patients-with-medical-history-of-cancer-and-anti-cd-20-treatment-49413https://curecurrent.com/trials/venetoclax-and-irinotecan-in-relapsed-refractory-sclc-49414https://curecurrent.com/trials/longitudinal-assessment-of-clinical-course-and-biomarkers-in-severe-chronic-airway-disease-49415https://curecurrent.com/trials/cancer-associated-thrombosis-and-isoquercetin-catiq-49416https://curecurrent.com/trials/immune-response-following-lobectomy-along-with-or-without-bilateral-transcervical-mediastinal-lymphadenectomy-49417https://curecurrent.com/trials/application-of-three-dimensionally-printed-navigational-template-in-lung-biopsy-49418https://curecurrent.com/trials/a-study-of-incagn01876-in-participants-with-advanced-or-metastatic-solid-tumors-49419https://curecurrent.com/trials/adjuvant-toripalimab-plus-chemotherapy-for-egfr-alk-mutation-negative-stage-ii-iiib-n2-nsclc-lungmate-008-49420https://curecurrent.com/trials/the-study-is-being-conducted-to-evaluate-the-efficacy-and-safety-of-shr-1316-in-combination-with-chemo-radiotherapy-in-p-49421https://curecurrent.com/trials/image-guided-and-breathing-adapted-radiotherapy-of-early-stage-lung-cancer-49422https://curecurrent.com/trials/a-personal-cancer-vaccine-neo-pv-01-with-pembrolizumab-and-chemotherapy-for-patients-with-lung-cancer-49423https://curecurrent.com/trials/evaluation-of-circulating-t-cells-and-tumor-infiltrating-lymphocytes-tils-during-after-pre-surgery-chemotherapy-in-non-s-49424https://curecurrent.com/trials/study-comparing-veliparib-plus-carboplatin-and-paclitaxel-versus-investigator-s-choice-of-standard-chemotherapy-in-adult-49425https://curecurrent.com/trials/needlescopic-assisted-uniportal-vs-uniportal-vats-49426https://curecurrent.com/trials/perceptions-of-exceptional-patients-in-cancer-care-relating-to-their-unusual-survival-49427https://curecurrent.com/trials/post-sbrt-pulmonary-metastasectomy-pspm-trial-49428https://curecurrent.com/trials/addition-of-microrna-blood-test-to-lung-cancer-screening-low-dose-ct-49429https://curecurrent.com/trials/a-randomized-phase-iii-study-of-palliative-radiation-of-advanced-central-tumors-with-intentional-avoidance-of-the-esopha-49430https://curecurrent.com/trials/transthoracic-needle-biopsy-using-3d-printed-navigational-template-a-phase-i-feasibility-trial-49431https://curecurrent.com/trials/determining-the-true-incidence-of-atrial-fibrillation-before-and-after-lung-resection-49432https://curecurrent.com/trials/a-personal-cancer-vaccine-neo-pv-01-w-nivolumab-for-patients-with-melanoma-lung-cancer-or-bladder-cancer-49433https://curecurrent.com/trials/evaluation-system-for-the-efficacy-of-immunologic-checkpoint-inhibitors-in-nsclc-49434https://curecurrent.com/trials/deep-inspiration-breath-hold-as-primary-strategy-for-locally-advanced-lung-cancer-radiotherapy-49435https://curecurrent.com/trials/efficacy-and-safety-of-use-of-platinum-based-doublet-chemotherapy-plus-antiangiogenesis-and-immune-checkpoint-inhibitors-49436https://curecurrent.com/trials/dacomitinib-treatment-followed-by-3rd-generation-egfr-tki-in-patients-with-egfr-mutation-positive-advanced-nsclc-49437https://curecurrent.com/trials/giotrif-rpms-in-korean-patients-with-nsclc-49438https://curecurrent.com/trials/incidence-of-venous-thromboembolism-in-patients-undergoing-major-esophageal-resection-49439https://curecurrent.com/trials/study-comparing-rovalpituzumab-tesirine-versus-topotecan-in-subjects-with-advanced-or-metastatic-small-cell-lung-cancer-49440https://curecurrent.com/trials/testing-afatinib-in-combination-with-pembrolizumab-in-patients-with-squamous-cell-carcinoma-of-the-lung-49441https://curecurrent.com/trials/clinical-trial-of-kanglaite-injection-klti-in-advanced-non-small-cell-lung-cancer-nsclc-49442https://curecurrent.com/trials/combination-chemotherapy-in-treating-patients-with-extensive-stage-small-cell-lung-cancer-49443https://curecurrent.com/trials/combination-chemotherapy-plus-peripheral-stem-cell-transplantation-in-treating-patients-with-small-cell-lung-cancer-49444https://curecurrent.com/trials/the-impact-of-polynuclear-neutrophils-intra-tumoral-rate-and-the-mutational-status-in-pulmonary-adenocarcinomas-on-survi-49445https://curecurrent.com/trials/phase-ii-safety-and-efficacy-study-of-crizotinib-in-east-asian-patients-with-ros1-positive-alk-negative-advanced-nsclc-49446https://curecurrent.com/trials/study-of-patupilone-in-patients-with-brain-metastasis-from-non-small-cell-lung-cancer-49447https://curecurrent.com/trials/mek162-for-patients-with-ras-raf-mek-activated-tumors-49448https://curecurrent.com/trials/neoadjuvant-durvalumab-anlotinib-chemotherapy-plus-curative-resection-in-stage-iii-non-small-cell-lung-cancer-a-single-a-49449https://curecurrent.com/trials/open-label-extension-study-of-conatumumab-and-ganitumab-amg-479-49450https://curecurrent.com/trials/grapiprant-ary-007-and-pembrolizumab-in-patients-with-advanced-or-metastatic-post-pd-1-l1-nsclc-adenocarcinoma-49451https://curecurrent.com/trials/losartan-in-treating-patients-with-idiopathic-pulmonary-fibrosis-49452https://curecurrent.com/trials/study-of-azd6738-and-olaparib-combination-therapy-in-relapsed-small-cell-lung-cancer-patients-sukses-n2-49453https://curecurrent.com/trials/olaparib-monotherapy-in-relapsed-small-cell-lung-cancer-patients-with-hr-pathway-gene-mutations-not-limited-to-brca-1-2-49454https://curecurrent.com/trials/circulating-tumour-dna-in-lung-cancer-citadel-optimizing-sensitivity-and-clinical-utility-49455https://curecurrent.com/trials/personalized-experiences-to-inform-improved-communication-for-minorities-with-life-limiting-illness-49456https://curecurrent.com/trials/a-single-arm-phase-clinical-trial-of-anlotinib-hydrochloride-combined-with-irinotecan-or-docetaxel-for-second-line-treat-49457https://curecurrent.com/trials/study-of-arsenic-trioxide-in-small-cell-lung-cancer-49458https://curecurrent.com/trials/lus-to-assess-lung-injury-after-lung-lobectomy-49459https://curecurrent.com/trials/chemoradiotherapy-in-stage-iii-non-small-cell-lung-cancer-nsclc-49460https://curecurrent.com/trials/ridaforolimus-with-cetuximab-adv-non-small-cell-lung-colorectal-head-neck-cancer-49461https://curecurrent.com/trials/pembrolizumab-with-nab-paclitaxel-in-non-small-cell-lung-cancer-49462https://curecurrent.com/trials/respiratory-syncytial-virus-rsv-protocol-49463https://curecurrent.com/trials/novel-light-delivery-methods-for-lung-cancer-photodynamic-therapy-a-pilot-study-49464https://curecurrent.com/trials/blood-sample-collection-in-subjects-with-pulmonary-nodules-or-ct-suspicion-of-lung-cancer-or-pathologically-diagnosed-lu-49465https://curecurrent.com/trials/blood-sample-collection-in-subjects-participating-in-a-lung-cancer-screening-program-49466https://curecurrent.com/trials/a-safety-study-of-oral-venetoclax-in-combination-with-intravenous-pembrolizumab-in-adult-participants-with-previously-un-49467https://curecurrent.com/trials/hx008-plus-chemotherapy-vs-pembrolizumab-plus-chemotherapy-as-the-first-line-treatment-in-participants-with-advanced-or-49468https://curecurrent.com/trials/nimotuzumab-combined-with-chemoradiotherapy-for-unresectable-locally-advanced-squamous-cell-lung-cancer-49469https://curecurrent.com/trials/biomarkers-of-stage-iii-locally-advanced-unresectable-non-small-cell-lung-cancer-49470https://curecurrent.com/trials/whole-exome-sequencing-wes-of-cancer-patients-49471https://curecurrent.com/trials/prevention-and-prophylaxis-of-cancer-associated-thrombosis-in-high-risk-oncology-patients-49472https://curecurrent.com/trials/prognostic-role-of-positron-emission-tomography-and-computed-tomography-parameters-in-stage-i-lung-adenocarcinoma-49473https://curecurrent.com/trials/toripalimab-combined-with-anlotinib-etoposide-and-platinum-in-the-treatment-of-extensive-stage-small-cell-lung-cancer-49474https://curecurrent.com/trials/immunotherapy-as-second-line-in-patient-with-small-cell-lung-cancer-49475https://curecurrent.com/trials/study-of-the-efficacy-of-sbrt-on-unresectable-peripheral-primary-tumor-49476https://curecurrent.com/trials/dce-ct-of-thoracic-tumors-as-an-early-biomarker-for-treatment-monitoring-in-comparison-with-morphologic-criteria-49477https://curecurrent.com/trials/randomized-study-on-effects-of-uniportal-vats-versus-triportal-vats-49478https://curecurrent.com/trials/clinical-characteristics-of-patients-with-leukemia-and-covid-19-49479https://curecurrent.com/trials/camrelizumab-combined-with-apatinib-etoposide-and-cisplatin-treat-small-cell-lung-cancer-49480https://curecurrent.com/trials/compare-apatinib-plus-chemotherapy-drug-versus-chemotherapy-drug-as-second-line-treatment-in-nsclc-49481https://curecurrent.com/trials/study-of-lp002-in-combination-with-chemotherapy-for-patients-with-extensive-stage-small-cell-lung-cancer-49482https://curecurrent.com/trials/multi-dimensional-precise-exploration-of-immunoconsolidation-therapy-for-locally-advanced-nsclc-after-chemo-radiotherapy-49483https://curecurrent.com/trials/phase-2-study-evaluating-mid-position-strategy-in-radiotherapy-treatment-for-patients-with-a-locally-advanced-non-small-49484https://curecurrent.com/trials/a-study-of-the-efficacy-and-safety-of-ro7198457-in-combination-with-atezolizumab-versus-atezolizumab-alone-following-adj-49485https://curecurrent.com/trials/study-of-different-doses-of-irinotecan-and-cisplatin-for-first-line-extensive-stage-small-cell-lung-cancer-treatment-49486https://curecurrent.com/trials/sgm-101-in-colorectal-lung-metastases-49487https://curecurrent.com/trials/retrospective-multi-center-study-to-compare-perioperative-outcomes-for-robotic-assisted-lobectomy-with-those-associated-49488https://curecurrent.com/trials/stereotactic-body-radiation-therapy-sbrt-in-newly-diagnosed-advanced-staged-lung-adenocarcinoma-sindas-49489https://curecurrent.com/trials/monitoring-alectinib-treatment-by-detection-of-alk-translocations-in-serial-blood-samples-from-non-small-cell-lung-cance-49490https://curecurrent.com/trials/monitoring-efficacy-of-radiotherapy-in-lung-cancer-and-esophageal-cancer-49491https://curecurrent.com/trials/a-phase-1-2-study-of-sc-43-in-combination-with-cisplatin-49492https://curecurrent.com/trials/a-remotely-supervised-exercise-program-for-lung-cancer-patients-undergoing-chemoradiation-rem-49493https://curecurrent.com/trials/bruog-l301-with-non-small-cell-lung-cancer-and-bone-metastases-49494https://curecurrent.com/trials/pcori-cer-1306-03385-informed-decisions-about-lung-cancer-screening-49495https://curecurrent.com/trials/simultaneous-integrated-boost-vs-routine-imrt-in-limited-stage-small-cell-lung-cancer-49496https://curecurrent.com/trials/imaging-nsclc-treatment-response-to-immunotherapy-49497https://curecurrent.com/trials/marker-guided-breathhold-radiotherapy-in-nsclc-49498https://curecurrent.com/trials/enb-guided-ablation-therapy-combined-with-vats-in-the-treatment-of-mplc-49499https://curecurrent.com/trials/nintedanib-and-weekly-docetaxel-in-lung-adenocarcinoma-49500https://curecurrent.com/trials/pyrotinib-plus-thalidomide-in-advanced-nsclc-patients-harboring-her2-exon-20-insertions-49501https://curecurrent.com/trials/once-daily-simultaneous-modulated-accelerated-thoracic-radiotherapy-in-limited-small-cell-lung-cancer-49502https://curecurrent.com/trials/study-in-patients-with-sclc-of-veliparib-in-combination-with-topotecan-49503https://curecurrent.com/trials/pulmonary-nodule-localization-prospective-validation-49504https://curecurrent.com/trials/neoadjuvant-toripalimab-combined-with-chemotherapy-in-the-treatment-of-malignant-pleural-mesothelioma-49505https://curecurrent.com/trials/lung-resection-and-pulmonary-rehabilitation-49506https://curecurrent.com/trials/pembrolizumab-with-chemotherapy-in-metastatic-or-unresectable-high-grade-gastroenteropancreatic-or-lung-neuroendocrine-c-49507https://curecurrent.com/trials/phase-ii-trial-of-hm61713-for-the-treatment-of-2nd-line-t790m-mutation-positive-adenocarcinoma-of-the-lung-49508https://curecurrent.com/trials/phase-ii-image-guided-stereotactic-ablative-radiotherapy-for-non-small-cell-lung-cancer-49509https://curecurrent.com/trials/study-of-the-combination-of-tivantinib-plus-pemetrexed-and-carboplatin-49510https://curecurrent.com/trials/combination-of-gemcitabine-and-imatinib-mesylate-in-pemetrexed-pretreated-patients-with-pleural-mesothelioma-49511https://curecurrent.com/trials/ipilimumab-and-nivolumab-in-the-treatment-of-malignant-pleural-mesothelioma-49512https://curecurrent.com/trials/a-study-of-ramucirumab-ly3009806-plus-medi4736-in-participants-with-advanced-gastrointestinal-or-thoracic-malignancies-49513https://curecurrent.com/trials/romidepsin-and-erlotinib-hydrochloride-in-treating-patients-with-stage-iii-or-stage-iv-non-small-cell-lung-cancer-49514https://curecurrent.com/trials/biomarkers-in-predicting-response-in-patients-with-early-stage-non-small-cell-lung-cancer-previously-treated-with-adjuva-49515https://curecurrent.com/trials/study-of-split-course-chemoradiotherapy-for-postoperative-locoregional-recurrence-of-non-small-cell-lung-cancer-49516https://curecurrent.com/trials/study-of-pegilodecakin-ly3500518-with-pembrolizumab-compared-to-pembrolizumab-alone-first-line-tx-in-participants-with-m-49517https://curecurrent.com/trials/real-world-data-of-nivolumab-in-pre-treated-nsclc-49518https://curecurrent.com/trials/assessment-of-the-effectiveness-of-local-ablathermy-radio-frequency-bronchial-tumors-primitive-49519https://curecurrent.com/trials/the-addition-of-metformin-to-definitive-radiotherapy-in-patients-with-stage-iii-nsclc-49520https://curecurrent.com/trials/pilot-digital-follow-up-of-lung-cancer-49521https://curecurrent.com/trials/circulating-tumor-dna-in-patients-diagnosed-with-lung-metastasis-from-colorectal-cancer-candidate-selection-for-local-ab-49522https://curecurrent.com/trials/a-study-to-evaluate-the-efficacy-of-bevacizumab-in-combination-with-tarceva-for-advanced-non-small-cell-lung-cancer-49523https://curecurrent.com/trials/fostering-efficacy-of-anti-pd-1-treatment-nivolumab-plus-radiotherapy-in-advanced-nsclc-49524https://curecurrent.com/trials/pyrotinib-combined-with-pemetrexed-plus-carboplatin-in-the-first-line-treatment-49525https://curecurrent.com/trials/a-phase-2-trial-of-almonertinib-with-concurrent-radiotherapy-in-the-treatment-of-local-advanced-egfr-mutant-nsclc-49526https://curecurrent.com/trials/albumin-bound-paclitaxel-and-gemcitabine-in-patients-with-untreated-stage-iv-or-recurrent-squamous-cell-lung-cancers-49527https://curecurrent.com/trials/comparison-between-endovascular-and-bronchoscopic-tumor-marker-insertion-for-real-time-stereotactic-guided-radiotherapy-49528https://curecurrent.com/trials/pd-1-knockout-engineered-t-cells-for-metastatic-non-small-cell-lung-cancer-49529https://curecurrent.com/trials/stereotactic-radiosurgery-or-other-local-ablation-then-erlotinib-in-epidermal-growth-factor-receptor-egfr-49530https://curecurrent.com/trials/intrapleural-measles-virus-therapy-in-patients-with-malignant-pleural-mesothelioma-49531https://curecurrent.com/trials/drug-drug-interaction-study-of-gefitinb-on-apatinib-in-nsclc-patients-49532https://curecurrent.com/trials/lung-cancer-in-women-treated-with-anti-oestrogens-and-inhibitors-of-egfr-49533https://curecurrent.com/trials/molecular-determinants-of-acquired-clinical-resistance-to-crizotinib-in-non-small-cell-lung-cancer-harboring-a-transloca-49534https://curecurrent.com/trials/anxiety-and-depression-perceived-by-individuals-with-and-without-cancer-during-the-covid-19-pandemic-period-49535https://curecurrent.com/trials/mk-3475-in-combination-with-docetaxel-vs-docetaxel-alone-in-non-small-cell-lung-cancer-patients-49536https://curecurrent.com/trials/combined-atezolizumab-and-chemotherapy-carboplatin-plus-etoposide-in-neoadjuvant-treating-limited-stage-small-cell-lung-49537https://curecurrent.com/trials/oral-epidermal-growth-factor-receptor-tyrosine-kinase-inhibitors-azd3759-or-azd9291-in-patients-who-have-advanced-non-sm-49538https://curecurrent.com/trials/comparative-genomic-profiling-of-lung-adenocarcinoma-in-asians-and-caucasians-a-propensity-matched-analysis-49539https://curecurrent.com/trials/central-nervous-system-cns-efficacy-of-dacomitinib-49540https://curecurrent.com/trials/magnetic-resonance-imaging-for-lung-radiotherapy-49541https://curecurrent.com/trials/investigation-of-an-abdominal-compression-device-49542https://curecurrent.com/trials/a-study-of-the-effect-of-r1507-in-combination-with-tarceva-erlotinib-on-progression-free-survival-in-patients-with-stage-49543https://curecurrent.com/trials/lung-cancer-screening-study-with-low-dose-ct-scan-and-blood-biomarker-49544https://curecurrent.com/trials/significance-of-early-mobilization-after-vats-l-49545https://curecurrent.com/trials/crizotinib-and-ganetespib-sta-9090-in-alk-positive-lung-cancers-49546https://curecurrent.com/trials/a-study-in-healthy-subjects-to-assess-bioavailability-proportion-of-a-drug-which-enters-the-circulation-to-have-an-activ-49547https://curecurrent.com/trials/resistance-to-oral-therapy-in-lung-cancer-49548https://curecurrent.com/trials/efficacy-and-safety-of-jmt101-combined-with-afatinib-or-osimertinib-in-patients-with-non-small-cell-lung-cancer-49549https://curecurrent.com/trials/a-study-of-asa404-or-placebo-in-combination-with-docetaxel-in-second-line-treatment-for-stage-iiib-iv-non-small-cell-lun-49550https://curecurrent.com/trials/aerobic-exercise-and-tai-chi-interventions-for-improving-survival-in-lung-cancer-patients-49551https://curecurrent.com/trials/camrelizumab-combined-with-apatinib-carboplatin-and-etoposide-in-participants-with-es-sclc-49552https://curecurrent.com/trials/anlotinib-plus-etoposide-and-carboplatin-as-first-line-treatment-for-extensive-stage-small-cell-lung-cancer-49553https://curecurrent.com/trials/afatinib-osimertinib-sequencing-nis-49554https://curecurrent.com/trials/asa404-or-placebo-in-combination-with-paclitaxel-and-carboplatin-as-first-line-treatment-for-stage-iiib-iv-non-small-cel-49555https://curecurrent.com/trials/treatment-patterns-outcomes-and-testing-in-egfrm-nsclc-patients-with-egfr-tki-1l-across-europe-reflect-49556https://curecurrent.com/trials/use-of-ebus-tbna-for-cell-culture-as-an-aid-to-diagnose-lung-cancer-and-lymphoma-49557https://curecurrent.com/trials/a-study-of-carboplatin-and-paclitaxel-with-or-without-medi-575-in-untreated-advanced-non-small-cell-lung-cancer-49558https://curecurrent.com/trials/the-molecular-epidemiology-of-epidermal-growth-factor-receptor-egfr-mutations-in-patients-with-advanced-egfr-mutation-po-49559https://curecurrent.com/trials/gsk1572932a-antigen-specific-cancer-immunotherapeutic-as-adjuvant-therapy-in-patients-with-non-small-cell-lung-cancer-49560https://curecurrent.com/trials/neuwave-flex-microwave-ablation-system-in-the-ablation-of-primary-soft-tissue-lesions-of-the-lung-49561https://curecurrent.com/trials/a-study-of-niraparib-as-maintenance-therapy-following-first-line-platinum-based-chemotherapy-in-patients-with-extensive-49562https://curecurrent.com/trials/analgesia-and-cancer-recurrence-lung-cancer-resection-49563https://curecurrent.com/trials/safety-of-everolimus-and-pemetrexed-in-lung-cancer-patients-49564https://curecurrent.com/trials/an-observational-study-to-evaluate-azd9291-treatment-in-patients-with-t790m-positive-non-small-cell-lung-cancer-49565https://curecurrent.com/trials/protocol-for-accelerated-recovery-in-patients-undergoing-thoracic-surgical-procedures-prosm-study-randomized-comparative-49566https://curecurrent.com/trials/combination-of-rad001-and-erlotinib-in-patients-with-advanced-non-small-cell-lung-cancer-previously-treated-only-with-ch-49567https://curecurrent.com/trials/safety-of-rad001-in-combination-with-cisplatin-and-etoposide-in-lung-cancer-patients-49568https://curecurrent.com/trials/safety-and-tolerability-of-pasireotide-lar-in-combination-with-everolimus-in-advanced-metastatic-nets-49569https://curecurrent.com/trials/key-performance-indicators-for-the-assessment-of-nsclc-patients-pathway-49570https://curecurrent.com/trials/a-study-of-emibetuzumab-in-combination-with-ramucirumab-ly3009806-in-participants-with-advanced-cancer-49571https://curecurrent.com/trials/phase-ib-study-of-ldk378-and-auy922-in-alk-rearranged-non-small-cell-lung-cancer-49572https://curecurrent.com/trials/anlotinib-plus-platinum-etoposide-in-first-line-of-extensive-stage-small-cell-lung-cancer-49573https://curecurrent.com/trials/volatil-organic-compounds-in-exhaled-air-and-sweat-after-thoracic-surgery-for-carcinological-resection-49574https://curecurrent.com/trials/pharmacokinetic-safety-and-efficacy-effects-of-oral-lbh589-on-dextromethorphan-in-patients-with-advanced-or-metastatic-n-49575https://curecurrent.com/trials/a-phase-i-multi-center-open-label-drug-drug-interaction-study-to-assess-the-effect-of-ceritinib-on-the-pharmacokinetics-49576https://curecurrent.com/trials/efficacy-safety-and-pharmacokinetics-of-qav680-versus-placebo-in-patients-with-asthma-49577https://curecurrent.com/trials/a-study-of-dbpr112-in-patients-with-head-and-neck-cancer-and-egfr-mutated-lung-cancer-49578https://curecurrent.com/trials/a-real-world-study-of-durvalumab-for-lung-cancer-in-china-49579https://curecurrent.com/trials/comparison-of-preoperative-ct-scan-guided-and-intraoperative-hybrid-dynact-scan-guided-small-lung-tumor-localization-49580https://curecurrent.com/trials/a-study-to-evaluate-the-impact-of-management-strategies-on-gastrointestinal-related-adverse-events-in-participants-with-49581https://curecurrent.com/trials/rational-approach-to-a-unilateral-pleural-effusion-49582https://curecurrent.com/trials/baduanjin-exercise-on-meridian-energy-lung-function-and-heart-rate-variability-in-patients-undergoing-lung-operative-49583https://curecurrent.com/trials/rational-approach-to-a-unilateral-pleural-effusion2-49584https://curecurrent.com/trials/study-of-safety-and-efficacy-of-lee011-and-ceritinib-in-patients-with-alk-positive-non-small-cell-lung-cancer-49585https://curecurrent.com/trials/intraoperative-conversion-during-video-assisted-thoracoscopy-resection-for-lung-cancer-does-not-alter-survival-49586https://curecurrent.com/trials/the-purpose-of-study-is-to-evaluate-the-safety-pharmacokinetics-and-anti-tumor-effects-of-ckd-702-in-patients-with-advan-49587https://curecurrent.com/trials/antineoplaston-therapy-in-treating-patients-with-stage-iv-lung-cancer-49588https://curecurrent.com/trials/a-phase-ii-open-label-multiple-arm-study-of-auy922-byl719-inc280-ldk378-and-mek162-in-chinese-patients-with-advanced-non-49589https://curecurrent.com/trials/advance-care-planning-evaluation-in-hospitalized-elderly-patients-49590https://curecurrent.com/trials/postoperative-pembrolizumab-for-the-patients-who-have-solid-predominant-or-micropapillary-lung-adenocarcinoma-with-patho-49591https://curecurrent.com/trials/robotic-bronchoscopy-for-peripheral-pulmonary-lesions-49592https://curecurrent.com/trials/impact-of-the-covid-19-infectious-epidemic-on-the-management-of-oncology-and-onco-hematology-patients-and-on-the-psychol-49593https://curecurrent.com/trials/real-world-study-of-efficacy-and-safety-of-atezolizumab-plus-chemotherapy-in-chinese-patients-with-es-sclc-49594https://curecurrent.com/trials/a-study-of-aflibercept-administered-in-combination-with-pemetrexed-and-cisplatin-in-participants-with-advanced-carcinoma-49595https://curecurrent.com/trials/effect-of-incidental-findings-information-on-lung-cancer-screening-intent-49596https://curecurrent.com/trials/exercise-program-among-lung-cancer-dyads-49597https://curecurrent.com/trials/an-open-label-phase-i-trial-of-intravenous-asa404-administered-in-combination-with-paclitaxel-and-carboplatin-in-japanes-49598https://curecurrent.com/trials/dinutuximab-and-irinotecan-versus-irinotecan-to-treat-subjects-with-relapsed-or-refractory-small-cell-lung-cancer-49599https://curecurrent.com/trials/a-study-of-fluzoparib-combined-with-apatinib-as-second-line-treatment-of-patients-with-extensive-stage-small-cell-lung-c-49600https://curecurrent.com/trials/a-study-of-ly3023414-and-necitumumab-in-squamous-lung-cancer-49601https://curecurrent.com/trials/a-study-of-crizotinib-versus-chemotherapy-in-previously-untreated-alk-positive-east-asian-non-small-cell-lung-cancer-pat-49602https://curecurrent.com/trials/vandetanib-in-advanced-nsclc-with-ret-rearrangement-49603https://curecurrent.com/trials/a-randomized-study-of-primary-tumor-radiotherapy-for-patients-with-stage-nsclc-49604https://curecurrent.com/trials/osteosarcoma-with-resectable-pulmonary-metastasis-a-retrospective-study-49605https://curecurrent.com/trials/study-of-nivolumab-for-advanced-cancers-in-india-49606https://curecurrent.com/trials/a-phase-ii-open-label-multicenter-study-of-capmatinib-in-subjects-with-met-exon-14-skipping-mutation-positive-advanced-n-49607https://curecurrent.com/trials/exercise-nutrition-and-palliative-care-in-advanced-lung-cancer-enpal-49608https://curecurrent.com/trials/almonertinib-with-chemotherapy-in-megfr-nsclc-49609https://curecurrent.com/trials/tepotinib-in-solid-tumors-harboring-met-alterations-49610https://curecurrent.com/trials/perception-of-the-covid-19-pandemic-in-patients-with-haematological-or-solid-neoplasias-49611https://curecurrent.com/trials/a-prospective-single-center-one-arm-clinical-study-of-apatinib-combined-with-chemotherapy-for-pretreated-patients-with-a-49612https://curecurrent.com/trials/pharmacokinetic-study-on-the-addition-of-aprepitant-to-cisplatin-etoposide-treatment-in-lung-cancer-patients-49613https://curecurrent.com/trials/a-study-with-pembrolizumab-for-non-small-cell-lung-cancer-nsclc-49614https://curecurrent.com/trials/maine-lung-cancer-coalition-using-chws-for-the-annual-lung-cancer-screening-reminder-49615https://curecurrent.com/trials/ipilimumab-and-stereotactic-body-radiation-therapy-sbrt-in-advanced-solid-tumors-49616https://curecurrent.com/trials/a-trial-of-shr-1316-maintenance-therapy-for-limited-stage-small-cell-lung-cancer-49617https://curecurrent.com/trials/phase-i-trial-of-afatinib-bibw-2992-and-dasatinib-in-non-small-cell-lung-cancer-nsclc-49618https://curecurrent.com/trials/smoky-coal-exposure-genetic-susceptibility-and-lung-cancer-in-non-smoking-women-in-china-49619https://curecurrent.com/trials/tarceva-and-radiotherapy-in-locally-advanced-lung-cancer-non-small-cell-lung-cancer-49620https://curecurrent.com/trials/expanded-access-program-with-nivolumab-therapy-for-treatment-of-advanced-metastatic-sqnsclc-or-non-sqnsclc-after-one-pri-49621https://curecurrent.com/trials/a-phase-ii-trial-of-upfront-radiotherapy-plus-almonertinib-for-epidermal-growth-factor-receptor-egfr-mutant-non-small-ce-49622https://curecurrent.com/trials/combination-nab-paclitaxel-n-p-and-nintedanib-or-n-p-and-placebo-in-relapsed-nsclc-adenocarcinoma-49623https://curecurrent.com/trials/photodynamic-therapy-in-treating-patients-with-resectable-non-small-cell-lung-cancer-that-has-spread-to-the-pleura-49624https://curecurrent.com/trials/a-survival-study-for-women-with-advanced-lung-cancer-who-have-not-previously-received-chemotherapy-49625https://curecurrent.com/trials/a-study-evaluates-the-safety-and-efficacy-of-wx-0593-in-alk-positive-or-ros1-positive-non-small-cell-lung-cancer-49626https://curecurrent.com/trials/paclitaxel-in-combination-with-bevacizumab-in-patients-with-stage-iv-nsclc-49627https://curecurrent.com/trials/radiation-therapy-chemotherapy-and-soy-isoflavones-in-treating-patients-with-stage-iiia-iiib-non-small-cell-lung-cancer-49628https://curecurrent.com/trials/testing-of-tak228-mln0128-sapanisertib-plus-docetaxel-to-the-usual-standard-of-care-for-advanced-squamous-cell-lung-canc-49629https://curecurrent.com/trials/vorinostat-in-combination-with-palliative-radiotherapy-for-patients-with-non-small-cell-lung-cancer-49630https://curecurrent.com/trials/radiation-therapy-in-treating-patients-with-non-small-cell-lung-cancer-that-has-been-completely-removed-by-surgery-49631https://curecurrent.com/trials/clinical-trial-of-the-safety-and-efficacy-of-the-addition-of-ramucirumab-to-nab-paclitaxel-in-previously-treated-patient-49632https://curecurrent.com/trials/role-of-circulating-tumor-dna-ctdna-from-liquid-biopsy-in-early-stage-nsclc-resected-lung-tumor-investigation-49633https://curecurrent.com/trials/ngs-based-comprehensive-genomic-ctdna-panel-in-nsclc-with-immunotherapy-49634https://curecurrent.com/trials/a-study-of-nab-paclitaxel-and-carboplatin-plus-necitumumab-ly3012211-in-participants-with-stage-iv-squamous-nsclc-49635https://curecurrent.com/trials/a-trial-of-anlotinib-combined-with-docetaxel-in-egfr-mutations-advanced-non-small-cell-lung-cancer-patients-49636https://curecurrent.com/trials/a-trial-of-anlotinib-combined-with-docetaxel-in-patients-with-wild-type-advanced-non-squamous-non-small-cell-lung-cancer-49637https://curecurrent.com/trials/use-of-a-smartphone-application-on-the-detection-of-complications-related-to-smoking-49638https://curecurrent.com/trials/study-comparing-veliparib-plus-carboplatin-and-paclitaxel-versus-placebo-plus-carboplatin-and-paclitaxel-in-previously-u-49639https://curecurrent.com/trials/a-multi-cancer-multi-state-platform-study-of-durvalumab-medi4736-and-oleclumab-medi9447-in-pancreatic-adenocarcinoma-non-49640https://curecurrent.com/trials/biomarkers-of-response-to-taxotere-in-hrpc-icorg-08-08-v2-49641https://curecurrent.com/trials/a-phase-2-study-of-durvalumab-medi4736-and-oleclumab-medi9447-in-multi-cancer-populations-with-correlation-to-clinical-m-49642https://curecurrent.com/trials/efficacy-and-safety-of-camrelizumab-in-real-world-study-49643https://curecurrent.com/trials/poziotinib-in-patients-with-nsclc-having-egfr-or-her2-exon-20-insertion-mutation-49644https://curecurrent.com/trials/pembrolizumab-defactinib-in-pleural-mesothelioma-49645https://curecurrent.com/trials/phase-2a-clinical-trial-to-evaluate-the-efficacy-and-safety-of-hl301-on-radiation-pneumonitis-in-non-small-cell-lung-can-49646https://curecurrent.com/trials/concordance-of-key-actionable-genomic-alterations-as-assessed-in-tumor-tissue-and-plasma-in-non-small-cell-lung-cancer-49647https://curecurrent.com/trials/improving-the-early-detection-of-lung-cancer-by-combining-exosomal-analysis-of-hypoxia-with-standard-of-care-imaging-49648https://curecurrent.com/trials/cognitive-and-behavioral-intervention-for-the-management-of-episodic-breathlessness-in-patients-with-advanced-disease-49649https://curecurrent.com/trials/topotecan-liposomes-injection-for-small-cell-lung-cancer-sclc-ovarian-cancer-and-other-advanced-solid-tumors-49650https://curecurrent.com/trials/trial-of-accupap-device-versus-standard-nebulizer-therapy-in-acute-asthma-exacerbation-in-children-49651https://curecurrent.com/trials/early-detection-of-lung-cancer-in-czech-high-risk-asymptomatic-individuals-49652https://curecurrent.com/trials/efficacy-of-continous-regional-anesthesia-using-m-erector-spinae-catheter-after-vats-procedures-49653https://curecurrent.com/trials/camrelizumab-with-chemotherapy-in-adults-with-medically-inoperable-early-stage-nsclc-49654https://curecurrent.com/trials/efficacy-and-safety-of-lgx818-in-patients-with-advanced-or-metastatic-braf-v600-mutant-nsclc-49655https://curecurrent.com/trials/to-evaluate-the-role-of-postoperative-radiotherapy-in-patients-with-iiia-n2-non-small-cell-lung-cancer-49656https://curecurrent.com/trials/radial-probe-endobronchial-ultrasound-in-detecting-atelectasis-in-patients-undergoing-peripheral-bronchoscopy-49657https://curecurrent.com/trials/effect-of-gtx-024-on-muscle-wasting-in-patients-with-non-small-cell-lung-cancer-nsclc-on-first-line-platinum-49658https://curecurrent.com/trials/tislelizumab-in-combination-with-anlotinib-with-es-sclc-as-maintenance-therapy-after-first-line-chemotherapy-49659https://curecurrent.com/trials/microwave-ablation-of-primary-and-secondary-lung-malignancies-49660https://curecurrent.com/trials/first-in-human-study-of-jnj-74699157-in-participants-with-tumors-harboring-the-kras-g12c-mutation-49661https://curecurrent.com/trials/mapping-sound-propagation-through-the-human-lung-for-better-diagnosis-49662https://curecurrent.com/trials/comparison-of-sublobar-resection-and-lobectomy-to-treat-lung-cancer-49663https://curecurrent.com/trials/novel-pleural-fluid-biopsy-and-serum-biomarkers-for-the-investigation-of-pleural-effusions-49664https://curecurrent.com/trials/hypofractionated-radiotherapy-with-carboplatin-and-paclitaxel-in-non-small-cell-lung-cancer-49665https://curecurrent.com/trials/effects-of-one-handed-and-two-handed-mask-ventilation-techniques-on-global-and-regional-lung-ventilation-49666https://curecurrent.com/trials/study-of-enzastaurin-versus-placebo-in-the-treatment-of-patients-with-brain-metastases-of-lung-cancer-after-whole-brain-49667https://curecurrent.com/trials/study-for-participants-with-advanced-not-amenable-to-surgery-or-metastatic-lung-cancer-comparing-treatment-with-pemetrex-49668https://curecurrent.com/trials/allogeneic-stem-cell-transplantation-in-chronic-myeloid-leukemia-failing-tkis-therapy-49669https://curecurrent.com/trials/a-multi-center-retrospective-analysis-of-clinical-character-outcome-and-prognosis-of-lymphoepithelioma-like-carcinoma-49670https://curecurrent.com/trials/nivolumab-in-combination-with-chemotherapy-or-nivolumab-in-combination-with-ipilimumab-in-advanced-egfr-mutant-or-alk-re-49671https://curecurrent.com/trials/effect-of-symptom-management-on-inflammation-and-survival-in-metastatic-lung-cancer-49672https://curecurrent.com/trials/a-randomized-phase-ii-study-of-stereotactic-ablative-body-radiotherapy-for-metastases-to-the-lung-trog-13-01-safron-ii-49673https://curecurrent.com/trials/18f-2-fluoro-2-deoxy-d-glucose-in-positron-emission-tomography-computed-tomography-49674https://curecurrent.com/trials/the-epic-trial-the-elderly-patient-individualized-chemotherapy-trial-49675https://curecurrent.com/trials/expanded-treatment-protocol-with-ldk378-in-alk-nsclc-49676https://curecurrent.com/trials/toripalimab-as-maintenance-therapy-in-patients-with-driver-gene-negative-advanced-nsclc-after-first-line-chemotherapy-49677https://curecurrent.com/trials/rh-endostatin-combined-with-ccrt-50-gy-followed-by-durvalumab-maintenance-for-the-treatment-of-specific-phase-iii-nsclc-49678https://curecurrent.com/trials/the-impacts-of-pulmonary-rehabilitation-therapy-on-patients-after-thoracic-surgery-49679https://curecurrent.com/trials/a-phase-ii-study-of-anti-pd-1-antibody-sintilimab-as-second-line-therapy-for-biomarker-selected-advanced-or-metastatic-n-49680https://curecurrent.com/trials/microwave-ablation-in-combination-with-camrelizumab-versus-camrelizumab-in-metastatic-non-small-cell-lung-cancer-49681https://curecurrent.com/trials/pilot-prehabilitation-intervention-in-lung-cancer-49682https://curecurrent.com/trials/ribociclib-in-treating-patients-with-advanced-neuroendocrine-tumors-of-foregut-origin-49683https://curecurrent.com/trials/the-covid-iyon-study-study-examining-data-pertaining-to-clinical-outcomes-and-organisational-responses-to-the-2020-sars-49684https://curecurrent.com/trials/efficacy-safety-and-pharmacokinetics-of-bcd-100-anti-pd-1-monotherapy-as-second-line-treatment-in-patients-with-non-smal-49685https://curecurrent.com/trials/kentucky-leads-collaborative-lung-cancer-survivorship-care-program-49686https://curecurrent.com/trials/perioperative-symptom-study-of-lung-cancer-cn-pro-lung-1-49687https://curecurrent.com/trials/depletion-of-myeloid-derived-suppressor-cells-to-enhance-anti-pd-1-therapy-49688https://curecurrent.com/trials/a-randomized-phase-2-study-of-ixabepilone-plus-carboplatin-and-paclitaxel-plus-carboplatin-in-advanced-nonsmall-cell-lun-49689https://curecurrent.com/trials/phase-i-combination-ixabepilone-cisplatin-49690https://curecurrent.com/trials/trial-specific-patient-decision-aid-tpda-of-the-immunosabr-phase-2-49691https://curecurrent.com/trials/suberoylanilide-hydroxamic-acid-vorinostat-mk-0683-versus-placebo-in-advanced-malignant-pleural-mesothelioma-mk-0683-014-49692https://curecurrent.com/trials/minimally-invasive-or-open-surgery-for-lung-cancer-pain-quality-of-life-and-economics-49693https://curecurrent.com/trials/the-relationship-between-the-tumor-markers-and-interstitial-lung-disease-49694https://curecurrent.com/trials/lung-map-taselisib-as-therapy-in-treating-patients-with-stage-iv-squamous-cell-lung-cancer-and-positive-biomarker-matche-49695https://curecurrent.com/trials/lung-cancer-screening-a-multilevel-intervention-49696https://curecurrent.com/trials/a-phase-2-study-of-ficlatuzumab-plus-erlotinib-vs-placebo-plus-erlotinib-in-subjects-with-previously-untreated-metastati-49697https://curecurrent.com/trials/a-single-center-prospective-cohort-study-for-pure-pulmonary-ground-glass-nodules-in-women-preparing-for-pregnancy-49698https://curecurrent.com/trials/bevacizumab-plus-egfr-tkis-in-chinese-patients-with-egfr-mutant-nsclc-a-real-world-study-49699https://curecurrent.com/trials/ct-2103-carboplatin-vs-paclitaxel-carboplatin-for-nsclc-in-women-with-estradiol-25-pg-ml-49700https://curecurrent.com/trials/chest-imaging-of-lung-nodule-s-under-high-frequency-non-invasive-ventilation-hf-niv-49701https://curecurrent.com/trials/trial-of-pf-00299804-in-patients-with-advanced-refractory-lung-cancer-49702https://curecurrent.com/trials/an-integrated-approach-to-treating-recurrent-thoracic-carcinomas-resistant-to-tyrosine-kinase-inhibitors-49703https://curecurrent.com/trials/almonertinib-pemetrexed-carboplatin-in-egfr-t790m-advanced-lung-cancer-49704https://curecurrent.com/trials/outcomes-of-elective-colorectal-cancer-surgery-during-covid-19-pandemic-implications-for-cancer-care-policy-49705https://curecurrent.com/trials/a-trial-of-belinostat-in-combination-with-erlotinib-in-patients-with-non-small-cell-lung-cancer-49706https://curecurrent.com/trials/study-of-oral-mifepristone-as-salvage-therapy-in-patients-with-advanced-or-metastatic-non-small-cell-lung-cancer-49707https://curecurrent.com/trials/clinical-trial-for-evaluating-efficacy-and-safety-of-pdr001-in-concurrent-plus-consolidation-versus-consolidation-only-i-49708https://curecurrent.com/trials/a-study-for-identification-of-predictive-immune-biomarker-in-peripheral-blood-for-nivolumab-therapy-in-nsclc-patients-49709https://curecurrent.com/trials/phase-i-iia-study-to-evaluate-the-safety-pk-pd-and-preliminary-efficacy-of-plx8394-in-patients-with-advanced-cancers-49710https://curecurrent.com/trials/study-of-activated-cytokine-induced-killer-armed-with-bispecific-antibody-for-advanced-lung-cancer-49711https://curecurrent.com/trials/almonertinib-as-upfront-treatment-for-uncommon-egfr-mutation-harboring-non-small-cell-lung-cancer-patients-a-multicenter-49712https://curecurrent.com/trials/nivolumab-and-metformin-hydrochloride-in-treating-patients-with-stage-iii-iv-non-small-cell-lung-cancer-that-cannot-be-r-49713https://curecurrent.com/trials/a-study-of-al2846-versus-zoledronic-acid-in-subjects-with-advanced-non-small-cell-lung-cancer-with-bone-metastasis-49714https://curecurrent.com/trials/comparison-between-wedge-resection-and-segmentectomy-for-ground-glass-opacity-dominant-stage-ia-nsclc-49715https://curecurrent.com/trials/reduced-dissemination-of-tumor-cells-with-primary-ligation-of-the-vein-in-patients-with-lung-cancer-49716https://curecurrent.com/trials/pain-and-impact-of-chronic-pain-on-function-after-total-knee-replacements-49717https://curecurrent.com/trials/whenii-early-response-evaluation-with-fdg-pet-ct-and-liquid-biopsy-in-patients-with-nsclc-49718https://curecurrent.com/trials/verification-of-novel-survival-prediction-algorithm-for-patients-with-nsclc-spinal-metastasis-49719https://curecurrent.com/trials/single-arm-on-the-tolerability-of-weekly-nab-paclitaxel-49720https://curecurrent.com/trials/pilot-study-to-investigate-the-diagnostic-yield-and-utility-of-22g-and-19g-endobronchial-ultrasound-transbronchial-needl-49721https://curecurrent.com/trials/effect-of-steroids-during-pneumocystis-infection-among-non-hiv-immunocompromised-patients-49722https://curecurrent.com/trials/erlotinib-hydrochloride-with-or-without-bevacizumab-in-treating-patients-with-stage-iv-non-small-cell-lung-cancer-with-e-49723https://curecurrent.com/trials/oncolytic-mg1-magea3-with-ad-magea3-vaccine-in-combination-with-pembrolizumab-for-non-small-cell-lung-cancer-patients-49724https://curecurrent.com/trials/polyglutamate-paclitaxel-plus-carboplatin-compared-with-paclitaxel-plus-carboplatin-in-treating-patients-with-advanced-o-49725https://curecurrent.com/trials/a-study-of-the-combination-of-necitumumab-ly3012211-and-pembrolizumab-mk3475-in-participants-with-nsclc-49726https://curecurrent.com/trials/carboplatin-with-either-paclitaxel-poliglumex-or-paclitaxel-in-treating-women-with-stage-iiib-stage-iv-or-recurrent-non-49727https://curecurrent.com/trials/a-study-to-reveal-the-patient-characteristics-and-treatment-patterns-of-stage-iii-non-small-cell-lung-cancer-patients-49728https://curecurrent.com/trials/postoperative-radiotherapy-for-patients-with-iiia-n2-non-small-cell-lung-cancer-49729https://curecurrent.com/trials/ethnic-racial-differences-in-metabolism-and-dna-adduct-formation-49730https://curecurrent.com/trials/polyglutamate-paclitaxel-compared-with-docetaxel-in-treating-patients-with-progressive-non-small-cell-lung-cancer-49731https://curecurrent.com/trials/polyglutamate-paclitaxel-compared-with-gemcitabine-or-vinorelbine-in-treating-patients-with-advanced-or-recurrent-non-sm-49732https://curecurrent.com/trials/role-of-fdg-pet-immune-and-hypoxic-marker-in-nsclc-49733https://curecurrent.com/trials/11c-methionine-pet-ct-imaging-in-patients-affected-by-malignant-pleural-mesothelioma-mpm-49734https://curecurrent.com/trials/efficacy-between-serratus-plane-block-and-local-infiltration-in-vats-49735https://curecurrent.com/trials/safety-and-efficacy-of-listeria-in-combination-with-chemotherapy-as-front-line-treatment-for-malignant-pleural-mesotheli-49736https://curecurrent.com/trials/covid-19-infection-in-cancer-pantients-49737https://curecurrent.com/trials/the-establishment-and-clinical-application-of-a-prediction-model-of-lung-cancer-distant-metastasis-based-on-the-genomic-49738https://curecurrent.com/trials/2nd-line-erlotinib-treatment-with-out-chemotherapy-of-advanced-non-small-cell-lung-cancer-nsclc-49739https://curecurrent.com/trials/paclitaxel-carboplatin-bevacizumab-nitroglycerin-in-metastatic-non-squamous-non-small-cell-lung-cancer-49740https://curecurrent.com/trials/clinical-study-of-ys110-in-patients-with-malignant-pleural-mesothelioma-49741https://curecurrent.com/trials/a-study-of-iressa-treatment-beyond-progression-in-addition-to-chemotherapy-versus-chemotherapy-alone-49742https://curecurrent.com/trials/procalcitonin-test-for-differentiation-of-the-cause-of-pneumonia-49743https://curecurrent.com/trials/pharmacokinetics-of-anti-tuberculosis-drugs-in-gastrectomized-patients-49744https://curecurrent.com/trials/thoracotomy-closure-technique-and-postoperative-pain-study-a-randomized-controlled-trial-49745https://curecurrent.com/trials/ph-1-study-in-subjects-with-tumors-requiring-arginine-to-assess-adi-peg-20-with-pemetrexed-and-cisplatin-49746https://curecurrent.com/trials/oncology-patient-reported-anxiety-mood-and-qol-during-the-covid-19-pandemic-49747https://curecurrent.com/trials/personalizing-immune-checkpoint-inhibitor-therapy-49748https://curecurrent.com/trials/gene-expression-levels-in-predicting-treatment-response-in-patients-with-stage-iv-non-small-cell-lung-cancer-49749https://curecurrent.com/trials/lume-bionis-a-biomarker-study-in-patients-with-nsclc-49750https://curecurrent.com/trials/a-trial-of-shr1701-combined-with-radiotherapy-for-metastatic-non-small-cell-lung-cancer-failure-after-first-line-treatme-49751https://curecurrent.com/trials/video-assisted-thoracoscopic-lobectomy-versus-conventional-open-lobectomy-for-lung-cancer-49752https://curecurrent.com/trials/evaluation-of-apricoxib-selective-cyclooxygenase-2-inhibition-in-modulating-t-regulatory-cells-of-patients-with-early-st-49753https://curecurrent.com/trials/a-preliminary-study-on-the-detection-of-plasma-markers-in-early-diagnosis-for-lung-cancer-49754https://curecurrent.com/trials/trial-of-endobronchial-ultrasound-guided-fine-needle-aspiration-techniques-49755https://curecurrent.com/trials/a-trial-of-placebo-versus-enzastaurin-for-lung-cancer-prevention-in-former-smokers-49756https://curecurrent.com/trials/derivation-and-validation-of-a-scoring-system-to-distinguish-cryptococcosis-and-adenocarcinoma-in-pulmonary-nodules-49757https://curecurrent.com/trials/molecular-imaging-visualization-of-tumor-heterogeneity-in-non-small-cell-lung-cancer-49758https://curecurrent.com/trials/mixed-reality-technique-combined-with-3d-printing-navigational-template-for-localizing-pulmonary-nodules-49759https://curecurrent.com/trials/efficacy-and-safety-of-bcd-100-anti-pd-1-in-combination-with-platinum-based-chemotherapy-as-first-line-treatment-in-pati-49760https://curecurrent.com/trials/safety-tolerability-pharmacokinetics-and-anti-tumour-activity-of-ask120067-in-locally-advanced-and-metastatic-non-small-49761https://curecurrent.com/trials/pemetrexed-disodium-with-or-without-erlotinib-hydrochloride-in-treating-patients-with-stage-iiib-iv-or-recurrent-non-sma-49762https://curecurrent.com/trials/phase-ib-ii-study-of-m3814-with-etoposide-and-cisplatin-in-small-cell-lung-cancer-sclc-extensive-disease-ed-49763https://curecurrent.com/trials/mesotrap-a-study-comparing-video-assisted-thoracoscopic-partial-pleurectomy-decortication-with-indwelling-pleural-cathet-49764https://curecurrent.com/trials/pulmonary-hypertension-in-patients-with-myeloproliferative-neoplasms-49765https://curecurrent.com/trials/stereotactic-body-radiotherapy-sbrt-versus-sublobar-resection-for-high-risk-patients-non-small-lung-cancer-49766https://curecurrent.com/trials/a-study-of-abemaciclib-ly2835219-in-combination-with-another-anti-cancer-drug-in-participants-with-lung-cancer-nsclc-49767https://curecurrent.com/trials/prediction-of-esophageal-and-lung-toxicities-after-radiation-chemo-therapy-49768https://curecurrent.com/trials/a-study-of-tq-b3139-capsules-in-subjects-with-met-altered-advanced-non-small-cell-lung-cancer-49769https://curecurrent.com/trials/study-of-pegilodecakin-ly3500518-with-nivolumab-compared-to-nivolumab-alone-second-line-tx-in-participants-with-metastat-49770https://curecurrent.com/trials/a-study-of-personalized-neoantigen-cancer-vaccines-49771https://curecurrent.com/trials/korea-study-korea-osimertinib-real-world-evidence-study-to-assess-safety-and-efficacy-49772https://curecurrent.com/trials/immunonutrition-to-reduce-toxicities-in-non-small-cell-lung-cancer-49773https://curecurrent.com/trials/pediatric-intensive-care-and-covid-19-49774https://curecurrent.com/trials/a-study-of-combination-therapy-in-nsclc-49775https://curecurrent.com/trials/a-prospective-study-comparing-two-radiotherapy-dose-fraction-and-omitting-ctvs-of-the-primary-tumor-in-limited-sclc-49776https://curecurrent.com/trials/camrelizumab-with-apatinib-as-neoadjuvant-therapy-for-participants-with-resectable-non-small-cell-lung-cancer-49777https://curecurrent.com/trials/a-phase-1b-2-study-of-omp-59r5-tarextumab-in-combination-with-etoposide-and-platinum-therapy-49778https://curecurrent.com/trials/a-study-of-carboplatin-and-pemetrexed-plus-demcizumab-omp-21m18-in-subjects-with-non-squamous-non-small-cell-lung-cancer-49779https://curecurrent.com/trials/airway-and-or-pulmonary-vessels-transplantation-49780https://curecurrent.com/trials/a-study-of-carboplatin-pemetrexed-plus-placebo-vs-carboplatin-pemetrexed-plus-1-or-2-truncated-courses-of-demcizumab-in-49781https://curecurrent.com/trials/a-study-of-vantictumab-omp-18r5-in-combination-with-docetaxel-in-patients-with-previously-treated-nsclc-49782https://curecurrent.com/trials/clinical-evaluation-of-pet-ct-for-staging-of-colorectal-lung-metastases-49783https://curecurrent.com/trials/analgesic-non-inferiority-of-the-thoracic-bi-block-in-comparison-with-thoracic-epidural-for-vats-49784https://curecurrent.com/trials/study-evaluating-the-efficacy-of-hydroxychloroquine-and-azithromycine-in-patients-with-covid-19-and-hematological-malign-49785https://curecurrent.com/trials/pemetrexed-disodium-and-hsp90-inhibitor-auy922-in-treating-patients-with-previously-treated-stage-iv-non-small-cell-lung-49786https://curecurrent.com/trials/developing-lung-cancer-screening-in-hodgkin-lymphoma-survivors-a-qualitative-study-49787https://curecurrent.com/trials/biomarkers-to-predict-the-response-to-pembrolizumab-in-chinese-nsclc-patients-49788https://curecurrent.com/trials/pci-for-patients-with-es-sclc-after-rct-a-prospective-randomized-study-49789https://curecurrent.com/trials/a-study-to-evaluate-the-efficacy-of-anti-emetic-drug-upon-the-combination-chemotherapy-for-non-small-cell-lung-cancer-49790https://curecurrent.com/trials/a-study-to-compare-the-similarity-in-efficacy-and-safety-between-trs003-and-china-approved-bevacizumab-in-nsclc-49791https://curecurrent.com/trials/radiofrequency-ablation-combined-with-melatonin-in-the-treatment-of-stage-ia-nsclc-49792https://curecurrent.com/trials/addition-of-radiotherapy-to-standard-medical-treatment-for-stage-iv-nsclc-49793https://curecurrent.com/trials/study-of-cm-24-mk-6018-alone-and-in-combination-with-pembrolizumab-mk-3475-in-participants-with-selected-advanced-or-rec-49794https://curecurrent.com/trials/epidural-anesthesia-analgesia-and-long-term-survival-after-lung-cancer-surgery-49795https://curecurrent.com/trials/high-dose-radiation-therapy-with-concurrent-chemotherapy-in-locally-advanced-non-small-cell-lung-cancer-49796https://curecurrent.com/trials/trimodal-lung-sparing-treatment-of-pleural-mesothelioma-49797https://curecurrent.com/trials/safety-of-simvastatin-in-lam-and-tsc-49798https://curecurrent.com/trials/study-of-radiotherapy-combined-with-albumin-bound-paclitaxel-and-nedaplatin-for-locally-advanced-nsclc-49799https://curecurrent.com/trials/assessing-an-oral-janus-kinase-inhibitor-azd4205-in-combination-with-osimertinib-in-patients-who-have-advanced-non-small-49800https://curecurrent.com/trials/erlotinib-and-sbrt-in-treating-patients-with-locally-advanced-or-metastatic-non-small-cell-lung-cancer-49801https://curecurrent.com/trials/trilaciclib-g1t28-a-cdk-4-6-inhibitor-in-combination-with-etoposide-and-carboplatin-in-extensive-stage-small-cell-lung-c-49802https://curecurrent.com/trials/comfort-level-of-two-abdominal-compression-methods-used-to-hold-patients-still-while-undergoing-stereotactic-body-radiat-49803https://curecurrent.com/trials/a-safety-and-efficacy-study-of-farletuzumab-in-participants-with-adenocarcinoma-of-the-lung-49804https://curecurrent.com/trials/4d-cone-beam-ct-reconstruction-for-radiotherapy-via-motion-vector-optimization-49805https://curecurrent.com/trials/specialized-radiation-therapy-in-treating-patients-with-stage-ii-stage-iii-stage-iv-or-recurrent-non-small-cell-lung-can-49806https://curecurrent.com/trials/using-rapid-cine-mri-for-monitoring-moving-and-deforming-tumors-49807https://curecurrent.com/trials/phase-ii-lung-metcore-preoperative-metformin-for-lung-cancer-49808https://curecurrent.com/trials/combination-chemotherapy-and-radiation-therapy-followed-by-surgery-in-treating-patients-with-stage-iib-or-stage-iiia-non-49809https://curecurrent.com/trials/randomised-trial-evaluating-the-benefit-of-a-fitness-tracker-based-workout-during-radiotherapy-49810https://curecurrent.com/trials/efficacy-and-safety-of-platinum-based-chemotherapy-bevacizumab-durvalumab-and-salvage-sbrt-for-iv-non-small-cell-lung-ca-49811https://curecurrent.com/trials/safety-and-efficacy-study-of-abraxane-as-maintenance-treatment-after-abraxane-plus-carboplatin-in-1st-line-stage-iiib-iv-49812https://curecurrent.com/trials/pembrolizumab-after-sbrt-versus-pembrolizumab-alone-in-advanced-nsclc-49813https://curecurrent.com/trials/efficacy-and-safety-of-sintilimab-with-or-without-radiotherapy-in-patients-with-recurrent-or-iv-nsclc-egfr-alk-after-fai-49814https://curecurrent.com/trials/effects-of-transcutaneous-electrical-nerve-stimulation-in-post-operative-lung-cancer-49815https://curecurrent.com/trials/pet-ct-re-planning-nsclc-4dct-pet-49816https://curecurrent.com/trials/covid-19-in-immunosuppressed-children-49817https://curecurrent.com/trials/capitalizing-on-a-teachable-moment-to-promote-smoking-cessation-49818https://curecurrent.com/trials/olmutinib-600-mg-qd-in-patients-with-t790m-positive-nsclc-after-treatment-with-an-egfr-tki-49819https://curecurrent.com/trials/effect-of-covid-19-pandemic-on-pediatric-cancer-care-49820https://curecurrent.com/trials/multicenter-study-of-rociletinib-administered-to-patients-with-previously-treated-mutant-egfr-non-small-cell-lung-cancer-49821https://curecurrent.com/trials/study-of-the-decrease-of-length-of-stereotactic-body-radiation-therapy-in-lung-cancer-49822https://curecurrent.com/trials/aimmune-artificial-intelligence-algorithm-for-identification-of-immunogenic-neoepitopes-of-cancer-to-predict-and-boost-p-49823https://curecurrent.com/trials/bioforte-technology-for-in-silico-identification-of-candidates-for-a-new-microbiome-based-therapeutics-and-diagnostics-49824https://curecurrent.com/trials/patient-reported-outcomes-registry-in-patient-with-cancer-cachexia-49825https://curecurrent.com/trials/a-study-of-gimatecan-st1481-in-small-cell-lung-cancer-49826https://curecurrent.com/trials/effect-of-lateral-positioning-on-bronchial-cuff-pressure-of-left-sided-double-lumen-endotracheal-tube-during-thoracic-su-49827https://curecurrent.com/trials/fluorine-f-18-feqa-in-patients-with-stage-iii-or-stage-iv-non-small-cell-lung-cancer-and-in-healthy-participants-49828https://curecurrent.com/trials/almonertinib-plus-chemotherapy-as-first-line-treatment-in-patients-with-egfr-concomitant-tumor-suppressor-gene-mutation-49829https://curecurrent.com/trials/almonertinib-plus-chemotherapy-as-first-line-treatment-in-patients-with-egfr-concomitant-non-egfr-driver-gene-mutant-loc-49830https://curecurrent.com/trials/prevention-of-venous-thromboembolism-following-radical-prostatectomy-49831https://curecurrent.com/trials/apixaban-or-dalteparin-in-reducing-blood-clots-in-patients-with-cancer-related-venous-thromboembolism-49832https://curecurrent.com/trials/bortezomib-in-kras-mutant-non-small-cell-lung-cancer-in-never-smokers-or-those-with-kras-g12d-49833https://curecurrent.com/trials/study-to-evaluate-safety-pharmacokinetics-and-efficacy-of-rociletinib-co-1686-in-previously-treated-mutant-epidermal-gro-49834https://curecurrent.com/trials/tumor-treating-fields-therapy-in-preventing-brain-tumors-in-participants-with-extensive-stage-small-cell-lung-cancer-49835https://curecurrent.com/trials/radiofrequency-ablation-in-treating-patients-with-refractory-or-advanced-lung-cancer-49836https://curecurrent.com/trials/covid-19-pandemic-and-pancreatic-surgery-in-italy-49837https://curecurrent.com/trials/gefitinib-with-chemotherapy-or-anti-angiogenesis-in-nsclc-patients-with-bim-deletion-or-low-egfr-mutation-abundance-49838https://curecurrent.com/trials/paclitaxel-and-carboplatin-with-or-without-celecoxib-before-surgery-in-treating-patients-with-stage-iiia-non-small-cell-49839https://curecurrent.com/trials/glucose-metabolism-in-patients-with-non-small-cell-lung-cancer-treated-with-targeted-therapy-and-chemotherapy-49840https://curecurrent.com/trials/avelumab-in-non-small-cell-lung-cancer-javelin-lung-200-49841https://curecurrent.com/trials/celecoxib-in-preventing-non-small-cell-lung-cancer-in-tobacco-smokers-49842https://curecurrent.com/trials/vaccine-therapy-in-treating-patients-with-stage-iiib-stage-iv-or-recurrent-non-small-cell-lung-cancer-49843https://curecurrent.com/trials/prospective-observation-of-failure-patterns-in-nsclc-treated-with-icis-49844https://curecurrent.com/trials/anlotinib-single-drug-as-the-maintenance-treatment-for-advanced-nsclc-49845https://curecurrent.com/trials/distribution-and-prognostic-impact-of-oncogenic-drivers-in-metastatic-lung-adenocarcinoma-a-retrospective-monocentric-st-49846https://curecurrent.com/trials/comparative-study-of-the-hypoxia-measured-in-faza-and-f-miso-pet-ct-scan-in-patients-with-non-small-cell-lung-cancer-49847https://curecurrent.com/trials/positive-end-expiratory-pressure-peep-in-predicting-fluid-responsiveness-in-patients-undergoing-one-lung-ventilation-49848https://curecurrent.com/trials/clinical-validation-of-inferread-lung-ct-ai-49849https://curecurrent.com/trials/pd1-msln-car-t-cells-for-the-treatment-of-msln-positive-advanced-solid-tumors-49850https://curecurrent.com/trials/using-npt-to-evaluate-providing-ppc-as-elnec-ppc-wbt-for-nurses-49851https://curecurrent.com/trials/clinical-study-of-neoantigen-vaccine-combined-with-targeted-drugs-in-the-treatment-of-non-small-cell-lung-cancer-49852https://curecurrent.com/trials/incorporation-of-genetic-expression-of-airway-epithelium-with-ct-screening-for-lung-cancer-49853https://curecurrent.com/trials/symptom-burden-and-unmet-supportive-care-needs-in-lung-cancer-patients-undergoing-first-or-second-line-immunotherapy-49854https://curecurrent.com/trials/binimetinib-with-docetaxel-in-treating-patients-with-previously-treated-stage-iv-non-small-cell-lung-cancer-49855https://curecurrent.com/trials/accelerated-hypofractionated-radiation-therapy-immediately-before-surgery-in-treating-patients-with-malignant-pleural-me-49856https://curecurrent.com/trials/sintilimab-after-stereotactic-ablation-brachytherapy-for-refractory-oligometastatic-non-small-cell-lung-cancer-49857https://curecurrent.com/trials/efficacy-and-safety-of-toripalimab-js001-combined-with-pemetrexed-and-anlotinib-for-patients-with-t790m-positive-non-sma-49858https://curecurrent.com/trials/apatinib-combined-with-chemotherapy-for-nsclc-patients-without-t790m-mutation-49859https://curecurrent.com/trials/influence-of-pet-ct-radiomic-features-on-the-outcome-of-lung-cancer-patients-49860https://curecurrent.com/trials/combination-of-osimertinib-and-aspirin-to-treat-osimertinib-resistance-non-small-cell-lung-cancer-nsclc-49861https://curecurrent.com/trials/tcm-in-the-treatment-of-lung-adenocarcinoma-49862https://curecurrent.com/trials/local-therapy-in-advanced-nsclc-with-non-progressive-disease-pd-after-first-line-therapy-49863https://curecurrent.com/trials/a-phase-1-study-of-zsp1602-in-participants-with-advanced-solid-tumors-49864https://curecurrent.com/trials/a-study-evaluating-the-efficacy-and-tolerability-of-veliparib-in-combination-with-paclitaxel-carboplatin-based-chemoradi-49865https://curecurrent.com/trials/nanospectrometer-biomarker-discovery-and-confirmation-study-49866https://curecurrent.com/trials/cryotherapy-in-treating-patients-with-primary-lung-cancer-or-lung-metastases-that-cannot-be-removed-by-surgery-49867https://curecurrent.com/trials/stereotactic-body-radiation-for-consolidation-after-standard-chemoradiation-for-stage-3-lung-cancer-49868https://curecurrent.com/trials/postoperative-radiotherapy-of-non-small-cell-lung-cancer-accelerated-vs-conventional-fractionation-49869https://curecurrent.com/trials/a-data-collection-study-for-patients-with-adenocarcinoma-treated-with-the-myvaccx-immunotherapy-regimen-49870https://curecurrent.com/trials/erlotinib-paclitaxel-and-carboplatin-combined-with-radiation-therapy-for-stage-iii-non-small-cell-lung-cancer-49871https://curecurrent.com/trials/preoperative-shielding-and-n-t-rt-pcr-swabbing-for-elective-cancer-surgery-49872https://curecurrent.com/trials/a-study-of-abbv-428-an-immunotherapy-in-subjects-with-advanced-solid-tumors-49873https://curecurrent.com/trials/a-study-of-rovalpituzumab-tesirine-administered-in-combination-with-nivolumab-and-with-or-without-ipilimumab-for-adults-49874https://curecurrent.com/trials/minocycline-study-in-non-small-cell-lung-cancer-nsclc-patients-for-chemoradiation-therapy-49875https://curecurrent.com/trials/descriptors-and-predictors-of-burden-and-information-needs-49876https://curecurrent.com/trials/cardiac-adverse-reactions-related-to-immune-checkpoint-inhibitor-in-nsclc-patients-49877https://curecurrent.com/trials/a-phase-i-study-of-fcn-411-in-advanced-non-small-cell-lung-cancer-chinese-patients-with-egfr-positive-mutation-49878https://curecurrent.com/trials/active-surveillance-in-early-lung-cancer-49879https://curecurrent.com/trials/a-study-of-tislelizumab-bgb-a317-plus-chemoradiotherapy-followed-by-tislelizumab-monotherapy-in-newly-diagnosed-stage-ii-49880https://curecurrent.com/trials/randomized-study-to-compare-cyberknife-to-surgical-resection-in-stage-i-non-small-cell-lung-cancer-49881https://curecurrent.com/trials/pazopanib-in-molecularly-selected-patients-with-advanced-nsclc-49882https://curecurrent.com/trials/thyroid-dysfunction-and-nivolumab-reponse-in-nsclc-49883https://curecurrent.com/trials/patient-activation-through-counseling-exercise-and-mobilization-49884https://curecurrent.com/trials/neoadjuvant-afatinib-combination-with-chemotherapy-for-stage-a-b-nsclc-with-egfr-activating-mutation-49885https://curecurrent.com/trials/car-t-cell-immunotherapy-for-advanced-lung-cancer-49886https://curecurrent.com/trials/safety-and-efficiency-of-t-cell-against-lung-cancer-49887https://curecurrent.com/trials/efficacy-and-safety-of-crt-durvalumab-and-surgery-for-sst-49888https://curecurrent.com/trials/s-1-plus-gefitinib-versus-gefitinib-monotherapy-in-patients-with-egfr-sensitive-mutation-advanced-non-squamous-nsclc-49889https://curecurrent.com/trials/study-of-apatinib-plus-etoposide-capsule-as-the-therapy-of-advanced-small-cell-lung-cancer-49890https://curecurrent.com/trials/the-effect-of-a-combined-drainage-strategy-in-uniportal-upper-lung-lobectomy-49891https://curecurrent.com/trials/safety-efficacy-and-pharmacokinetics-of-ald518-in-patients-with-non-small-cell-lung-cancer-related-fatigue-and-cachexia-49892https://curecurrent.com/trials/a-study-of-necitumumab-and-abemaciclib-in-participants-with-non-small-cell-lung-cancer-nsclc-49893https://curecurrent.com/trials/cm082-and-js001-in-patients-with-advanced-non-small-cell-lung-cancer-nsclc-49894https://curecurrent.com/trials/cm082-and-js001-in-patients-with-advanced-small-cell-lung-cancer-sclc-49895https://curecurrent.com/trials/efficacy-of-a-maintenance-treatment-with-talazoparib-following-first-line-platinum-based-chemotherapy-in-malignant-mesot-49896https://curecurrent.com/trials/a-study-of-asn007-in-patients-with-advanced-solid-tumors-49897https://curecurrent.com/trials/a-study-to-evaluate-the-tolerance-pharmacokinetics-and-efficacy-of-tq-a3334-tablets-49898https://curecurrent.com/trials/trial-in-extensive-disease-small-cell-lung-cancer-ed-sclc-subjects-comparing-ipilimumab-plus-etoposide-and-platinum-ther-49899https://curecurrent.com/trials/erlotinib-hydrochloride-before-surgery-in-treating-patients-with-stage-iii-non-small-cell-lung-cancer-49900https://curecurrent.com/trials/advanced-endoscopy-during-covid-19-49901https://curecurrent.com/trials/inpatient-smokers-and-ldct-screening-part-2-49902https://curecurrent.com/trials/methylated-dna-detect-in-paraneoplastic-syndrome-of-nervous-system-49903https://curecurrent.com/trials/cs-7017-in-combination-with-carboplatin-paclitaxel-in-subjects-with-stage-iiib-iv-non-small-cell-lung-cancer-nsclc-49904https://curecurrent.com/trials/study-of-autologous-cik-cell-immunotherapy-combination-with-pd-1-inhibitor-and-chemotherapy-in-the-advanced-nsclc-49905https://curecurrent.com/trials/js001-combination-therapy-in-nsclc-negative-driving-gene-after-first-line-chemotherapy-49906https://curecurrent.com/trials/multimodality-treatment-including-curative-resection-of-advanced-nsclc-49907https://curecurrent.com/trials/adjuvant-afatinib-in-stage-i-iii-nsclc-with-egfr-mutation-49908https://curecurrent.com/trials/study-of-autologous-cytotoxic-t-lymphocyte-immunotherapy-combination-with-pd-1-inhibitor-in-the-advanced-nsclc-49909https://curecurrent.com/trials/change-in-nlr-and-survival-among-advanced-lung-cancer-patients-receiving-icis-with-immunomodulator-49910https://curecurrent.com/trials/building-a-multidisciplinary-bridge-across-the-quality-chasm-in-thoracic-oncology-49911https://curecurrent.com/trials/almonertinib-vs-erlotinib-chemotherapy-for-neo-adjuvant-treatment-of-stage-iiia-n2-egfr-mutated-nsclc-49912https://curecurrent.com/trials/prospective-analysis-of-morbi-mortality-of-patients-with-cancers-in-active-phase-of-treatment-suspected-or-diagnosed-of-49913https://curecurrent.com/trials/a-study-of-sequential-therapy-of-camrelizumab-combined-with-chemotherapy-irinotecan-plus-platinum-and-with-apatinib-in-p-49914https://curecurrent.com/trials/clinical-and-histopathologic-characteristics-of-bap1-mutations-49915https://curecurrent.com/trials/alternating-icotinib-and-chemotherapy-for-advanced-non-small-cell-lung-cancer-with-egfr-mutation-49916https://curecurrent.com/trials/study-of-enzastaurin-versus-placebo-with-pemetrexed-for-participants-with-advanced-or-metastatic-lung-cancer-49917https://curecurrent.com/trials/combination-chemotherapy-with-or-without-anlotinib-in-the-maintenance-treatment-of-non-squamous-non-small-cell-lung-canc-49918https://curecurrent.com/trials/phase-1b-safety-study-of-cmb305-in-patients-with-locally-advanced-relapsed-or-metastatic-cancer-expressing-ny-eso-1-49919https://curecurrent.com/trials/respiratory-function-of-dexmedetomidine-in-patients-undergoing-pleuroscopy-49920https://curecurrent.com/trials/ct-based-radiomic-algorithm-for-assisting-surgery-decision-and-predicting-immunotherapy-response-of-nsclc-49921https://curecurrent.com/trials/cigarette-smoking-and-oral-microbiota-49922https://curecurrent.com/trials/effect-of-hyponatremia-in-small-cell-lung-cancer-49923https://curecurrent.com/trials/genetic-epidemiology-of-lung-cancer-and-smoking-49924https://curecurrent.com/trials/sentinel-impact-of-the-use-of-a-web-application-for-the-detection-of-lung-cancer-relapse-49925https://curecurrent.com/trials/pulmonary-and-extrapulmonary-impairments-in-patients-with-lung-cancer-awaiting-surgery-49926https://curecurrent.com/trials/an-epidemiology-study-to-determine-the-prevalence-of-egfr-epidermal-growth-factor-receptor-mutations-in-russian-patients-49927https://curecurrent.com/trials/biological-factors-predicting-response-to-chemotherapy-in-advanced-non-small-cell-lung-cancer-49928https://curecurrent.com/trials/monitoring-of-circulating-tumor-dna-and-its-aberrant-methylation-in-the-surveillance-of-surgical-lung-cancer-patients-me-49929https://curecurrent.com/trials/topotecan-hydrochloride-or-cyclodextrin-based-polymer-camptothecin-crlx101-in-treating-patients-with-recurrent-small-cel-49930https://curecurrent.com/trials/microwave-ablation-in-pulmonary-malignancies-49931https://curecurrent.com/trials/study-of-carotuximab-trc105-plus-nivolumab-in-patients-with-metastatic-nsclc-49932https://curecurrent.com/trials/pemetrexed-in-advanced-non-small-cell-lung-cancer-at-progression-vs-maintenance-therapy-after-induction-chemotherapy-49933https://curecurrent.com/trials/a-feasibility-study-of-chinese-herbs-to-manage-cancer-related-symptoms-in-patients-with-advanced-nsclc-49934https://curecurrent.com/trials/feasibility-of-wearable-activity-trackers-for-detection-of-toxicity-in-people-receiving-systemic-anticancer-treatment-49935https://curecurrent.com/trials/the-detection-of-egfr-mutations-in-liquid-based-cytology-samples-49936https://curecurrent.com/trials/characterisation-of-gut-microbiota-bispectral-index-data-and-plasma-kynurenine-in-patients-undergoing-video-assisted-tho-49937https://curecurrent.com/trials/does-the-incremental-shuttle-walk-test-predict-the-development-of-a-hospital-acquired-pneumonia-in-patients-undergoing-e-49938https://curecurrent.com/trials/a-efficacy-and-safety-study-of-anlotinib-hydrochloride-capsule-combined-with-chemotherapy-versus-placebo-combined-with-c-49939https://curecurrent.com/trials/a-multicenter-expanded-access-treatment-protocol-of-lurbinectedin-in-previously-treated-sclc-in-the-usa-49940https://curecurrent.com/trials/atom-local-ablative-therapy-49941https://curecurrent.com/trials/phase-3-trial-in-squamous-non-small-cell-lung-cancer-subjects-comparing-ipilimumab-versus-placebo-in-addition-to-paclita-49942https://curecurrent.com/trials/phase-1b-dv281-with-an-anti-pd-1-inhibitor-in-nsclc-49943https://curecurrent.com/trials/covid-19-in-pediatric-oncology-and-hematology-centers-in-france-49944https://curecurrent.com/trials/assessment-of-functional-capacity-pain-cognitive-and-respiratory-functions-in-lung-cancer-survivors-49945https://curecurrent.com/trials/the-canada-lymph-node-score-a-feasibility-randomized-controlled-trial-49946https://curecurrent.com/trials/oral-care-study-of-postoperative-infections-49947https://curecurrent.com/trials/study-of-erlotinib-with-or-without-investigational-drug-cs-7017-in-subjects-with-advanced-non-small-cell-lung-cancer-49948https://curecurrent.com/trials/prediction-of-immunotherapeutic-effect-of-advanced-non-small-cell-lung-cancer-49949https://curecurrent.com/trials/lung-dose-in-patients-treated-with-yttrium-90-for-hepatocellular-carcinoma-49950https://curecurrent.com/trials/cta-expression-methylation-and-response-to-pembrolizumab-of-nsclc-patients-49951https://curecurrent.com/trials/prospective-genomics-initiative-on-multiple-synchronous-lung-cancer-pgi-mslc-49952https://curecurrent.com/trials/phase-i-study-of-individualized-neoantigen-peptides-in-the-treatment-of-egfr-mutant-non-small-cell-lung-cancer-49953https://curecurrent.com/trials/camrelizumab-combined-with-apatinib-mesylate-and-standard-chemotherapy-pemetrixed-carboplatin-in-patients-with-tyrosine-49954https://curecurrent.com/trials/osimertinib-with-bevacizumab-for-leptomeningeal-metastasis-from-egfr-mutation-non-small-cell-lung-cancer-49955https://curecurrent.com/trials/study-of-sintlimab-maintenance-therapy-in-patients-with-extensive-small-cell-lung-cancer-49956https://curecurrent.com/trials/lymphadenectomy-in-nsclc-with-and-without-adjuvant-therapy-49957https://curecurrent.com/trials/a-study-of-shr-1210-in-combination-with-pemetrexed-and-carboplatin-in-subjects-with-non-squamous-nsclc-49958https://curecurrent.com/trials/a-study-of-ramucirumab-ly3009806-in-combination-with-weekly-docetaxel-in-participants-with-stage-iv-non-small-cell-lung-49959https://curecurrent.com/trials/incmga00012-in-combination-with-chemoradiation-in-participants-with-stage-iii-non-small-cell-lung-cancer-pod1um-301-49960https://curecurrent.com/trials/food-as-medicine-an-rct-to-study-the-effect-of-home-delivered-medically-tailored-meals-on-patients-with-metastatic-cance-49961https://curecurrent.com/trials/study-to-evaluate-concordance-of-detecting-egfr-epidermal-growth-factor-receptor-mutation-by-circulating-tumour-free-dna-49962https://curecurrent.com/trials/study-kbp-2020-cphg-documenting-new-cases-of-primary-lung-cancer-plc-diagnosed-in-respiratory-medicine-departments-and-l-49963https://curecurrent.com/trials/escap-2020-cphg-treatment-strategies-follow-up-implemented-during-the-first-three-years-following-primary-lung-cancer-pl-49964https://curecurrent.com/trials/x-396-ensartinib-capsules-in-alk-positive-nsclc-patients-with-brain-metastases-49965https://curecurrent.com/trials/bronchoscopy-screening-for-high-risk-population-of-lung-cancer-with-severe-smoking-with-negative-ldct-screen-49966https://curecurrent.com/trials/detection-of-lung-cancer-by-plasma-lipids-49967https://curecurrent.com/trials/survivin-and-fibulin-3-in-benign-and-malignant-respiratory-diseases-49968https://curecurrent.com/trials/cfdna-methylation-assay-for-clinical-evaluation-of-patients-with-stage-ia-lung-cancer-after-ablation-operation-49969https://curecurrent.com/trials/study-of-agen1884-with-pembrolizumab-in-1l-nsclc-49970https://curecurrent.com/trials/interest-of-procore-needle-for-diagnosis-of-lung-cancer-49971https://curecurrent.com/trials/a-phase-ib-study-with-pegylated-recombinant-human-endostatin-in-advanced-metastatic-nsclc-or-other-solid-tumors-49972https://curecurrent.com/trials/neuwave-flexible-probe-study-2-49973https://curecurrent.com/trials/a-phase-2-study-of-crlx101-nlg207-in-patients-with-advanced-non-small-cell-lung-cancer-49974https://curecurrent.com/trials/pd-1-immune-checkpoint-inhibitors-and-immune-related-adverse-events-a-cohort-study-49975https://curecurrent.com/trials/immunotherapy-study-in-progressive-or-relapsed-non-small-cell-lung-cancer-49976https://curecurrent.com/trials/vaccine-treatment-for-advanced-non-small-cell-lung-cancer-49977https://curecurrent.com/trials/vaccine-maintenance-treatment-for-non-small-cell-lung-cancer-49978https://curecurrent.com/trials/a-study-of-syha1807-in-subjects-with-extensive-stage-small-cell-lung-cancer-49979https://curecurrent.com/trials/efficacy-and-safety-of-recombinant-human-endostatin-in-non-small-cell-lung-cancer-with-leptomeningeal-metastasis-49980https://curecurrent.com/trials/cryotherapy-combine-icotinib-for-advanced-nsclc-treatment-49981https://curecurrent.com/trials/efficacy-and-safety-of-durvalumab-in-non-small-cell-lung-cancer-with-leptomeningeal-metastasis-49982https://curecurrent.com/trials/trial-of-image-guided-adaptive-conformal-photon-vs-proton-therapy-with-concurrent-chemotherapy-for-locally-advanced-non-49983https://curecurrent.com/trials/a-study-to-evaluate-the-safety-tolerability-and-antitumor-activity-of-incb001158-plus-epacadostat-with-or-without-pembro-49984https://curecurrent.com/trials/acetylsalicylic-acid-compared-to-placebo-in-treating-high-risk-patients-with-subsolid-lung-nodules-49985https://curecurrent.com/trials/the-role-of-18f-fdg-pet-ct-scan-in-lung-cancer-patients-49986https://curecurrent.com/trials/a-study-of-bio-11006-in-the-treatment-of-advanced-non-small-cell-lung-cancer-49987https://curecurrent.com/trials/all-in-one-study-a-prospective-trial-of-electromagnetic-navigation-for-biopsy-of-pulmonary-nodules-49988https://curecurrent.com/trials/pembrolizumab-plus-amurubicin-in-patients-with-refractory-small-cell-lung-cancer-49989https://curecurrent.com/trials/a-study-of-canakinumab-in-patients-with-systemic-juvenile-idiopathic-arthritis-or-hereditary-periodic-fevers-who-partici-49990https://curecurrent.com/trials/biomarkers-in-the-nose-throat-and-lung-tissue-of-smokers-and-non-smokers-49991https://curecurrent.com/trials/13-cis-retinoic-acid-with-or-without-vitamin-e-for-prevention-of-lung-cancer-49992https://curecurrent.com/trials/dose-escalation-and-double-blind-study-of-veliparib-in-combination-with-carboplatin-and-etoposide-in-treatment-naive-ext-49993https://curecurrent.com/trials/iloprost-in-preventing-lung-cancer-in-patients-at-high-risk-for-this-disease-49994https://curecurrent.com/trials/study-of-pembrolizumab-mk-3475-in-participants-with-advanced-non-small-cell-lung-cancer-mk-3475-025-keynote-025-49995https://curecurrent.com/trials/study-of-carboplatin-paclitaxel-with-or-without-investigational-drug-cs-7017-in-subjects-with-metastatic-non-small-cell-49996https://curecurrent.com/trials/outcomes-of-elective-cancer-surgery-during-the-covid-19-pandemic-crisis-49997https://curecurrent.com/trials/docetaxel-suramin-in-2nd-line-advanced-non-small-cell-lung-cancer-49998https://curecurrent.com/trials/improving-resection-rates-among-african-americans-with-nsclc-49999https://curecurrent.com/trials/covid19-convalescent-plasma-for-treating-patients-with-active-symptomatic-covid-19-infection-falp-covid-50000